



US010351631B2

(12) United States Patent
Keyt et al.**(10) Patent No.: US 10,351,631 B2**
(45) Date of Patent: Jul. 16, 2019**(54) CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES****(71) Applicant: IGM Biosciences, Inc., Mountain View, CA (US)****(72) Inventors: Bruce Alan Keyt, Hillsborough, CA (US); Fen Zhang, San Francisco, CA (US); Leonard George Presta, San Francisco, CA (US); Rency Yoshimura, Santa Clara, CA (US)****(73) Assignee: IGM BIOSCIENCES, INC., Mountain View, CA (US)****(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.**(21) Appl. No.: 14/916,166****(22) PCT Filed: Sep. 4, 2014****(86) PCT No.: PCT/US2014/054079**

§ 371 (c)(1),

(2) Date: Mar. 2, 2016**(87) PCT Pub. No.: WO2015/053887****PCT Pub. Date: Apr. 16, 2015****(65) Prior Publication Data**

US 2016/0222132 A1 Aug. 4, 2016

Related U.S. Application Data**(60)** Provisional application No. 61/874,277, filed on Sep. 5, 2013, provisional application No. 61/874,284, filed on Sep. 5, 2013.**(51) Int. Cl.****C07K 16/00** (2006.01)**A61K 39/00** (2006.01)**C07K 16/46** (2006.01)**C07K 16/28** (2006.01)**(52) U.S. Cl.**CPC **C07K 16/468** (2013.01); **C07K 16/00** (2013.01); **C07K 16/2809** (2013.01); **C07K 16/2887** (2013.01); **C07K 16/461** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/35** (2013.01); **C07K 2317/52** (2013.01); **C07K 2317/522** (2013.01); **C07K 2317/524** (2013.01); **C07K 2317/526** (2013.01); **C07K 2317/528** (2013.01); **C07K 2317/64** (2013.01)**(58) Field of Classification Search**

None

See application file for complete search history.

(56) References Cited**U.S. PATENT DOCUMENTS**

4,816,567 A	3/1989	Cabilly et al.	
8,349,332 B2 *	1/2013	Chang	A61K 47/48415 424/130.1
8,377,435 B2	2/2013	Bhat	
9,409,976 B2	8/2016	Teng	
9,458,241 B2	10/2016	Bhat	
9,938,347 B2	4/2018	Wang	
9,951,134 B2	4/2018	Keyt	
2002/0062010 A1 *	5/2002	Arathoon	C07K 16/00 530/388.1
2006/0063234 A1	3/2006	Jones	
2007/0014794 A1 *	1/2007	Carter	C07K 14/70514 424/143.1
2010/0286374 A1 *	11/2010	Kannan	C07K 16/468 530/387.3
2010/0316645 A1 *	12/2010	Imhof-Jung	C07K 16/22 424/136.1
2013/0089547 A1 *	4/2013	Tso	C07K 16/2803 424/134.1
2013/0129723 A1	5/2013	Blankenship et al.	
2016/0326233 A1	11/2016	Mondelli	
2016/0368971 A1	12/2016	Keyt	
2017/0283510 A1	10/2017	Keyt	
2018/0009897 A1	1/2018	Wang	
2018/0118814 A1	5/2018	Carroll	
2018/0118816 A1	5/2018	Keyt	

FOREIGN PATENT DOCUMENTS

JP	2008512987	5/2008
JP	2011508604	3/2011
WO	WO 1989/001975	3/1898
WO	WO 1996/027011	9/1996
WO	2006008548	1/2006
WO	WO 2006/008548 A2	1/2006

(Continued)

OTHER PUBLICATIONS

Muller et al., PNAS, 2013, 110:10183-10188 (Year: 2013).*

Kontermann et al. (Bispecific Antibodies, 2011, pp. 1-373), (Year: 2011).*

Atwell et al., "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library," J. Mol. Biol. 1997, vol. 270, pp. 26-35.

Choi et al., "Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro," Eur J Immunol. 2001, vol. 31, No. 1, pp. 94-106.

(Continued)

Primary Examiner — Julie Wu

(74) Attorney, Agent, or Firm — FisherBroyles, LLP**(57) ABSTRACT**

The present invention concerns binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same. The invention further concerns multi-specific binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same.

22 Claims, 30 Drawing Sheets**Specification includes a Sequence Listing.**IPR2025-00605
Patent Owner's Exhibit 2018
Page 000001

EXHIBIT	4003
WIT:	Presta
DATE:	12-5-25
CARLA SOARES, CSR	

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	2009089004	7/2009
WO	WO 2009/089004 A1	7/2009
WO	2013049254	4/2013
WO	2013096291	6/2013
WO	2016141303	9/2016
WO	2017059380	4/2017
WO	2017059387	4/2017
WO	2017196867	11/2017
WO	2018017761	1/2018
WO	2018017763	1/2018
WO	2018017888	1/2018
WO	2018017889	1/2018

OTHER PUBLICATIONS

Clackson et al., "Making antibody fragments using phage display libraries," *Nature*, 1991, vol. 352, pp. 624-628.

Czajkowsky and Shao, "The human IgM pentamer is a mushroom-shaped molecule with a flexural bias," *PNAS* 2009, vol. 106, No. 35, pp. 14960-14965.

Diaz, Maria Aiko Angela A., "Effects of engineering charged amino acids in the C_H3 domains on antibody heavy chain dimerization," *Philippine Science Letters*, 2011, vol. 4, No. 1, pp. 48-55.

Ellman, "Biosynthetic method for introducing unnatural amino acids site-specifically into proteins," *Meth. Enzym.* 1991, vol. 202, pp. 301-336.

Fegan, et al., "Chemically self-assembled antibody nanostructures as potential drug carriers," *Mol Pharm.* 2012, vol. 9, No. 11, pp. 3218-3227.

GenBank Accession No. AFM37312.1 (2 pages).

GenBank Accession No. CAB37838.1 (2 pages).

GenBank Accession No. CAC20458.1 (2 pages).

GenBank Accession No. J00260.1 (2 pages).

GenBank Accession No. X14940.1 (3 pages).

GenBank Accession No. X57331.1 (7 pages).

Giesse et al., "Eukaryotic expression systems: a comparison," *Protein Expr. Purif.* 1996, vol. 8, pp. 271-282.

Gunasekaran et al., "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG," *J. Biol. Chem.* 2010, vol. 285, No. 25, pp. 19637-19646.

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature* 1986, vol. 321, pp. 522-525.

Kaufman, R. J., "Overview of vector design for mammalian gene expression," *Mol. Biotechnol.* 2000, vol. 16, No. 2, pp. 151-161.

Klein et al., "Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies," *MAbs* 2012, vol. 4, No. 6, pp. 653-663.

Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature*, 1975, vol. 256, p. 495.

Makrides, S.C., "Components of vectors for gene transfer and expression in mammalian cells," *Protein Expr. Purif.* 1999, vol. 17, pp. 183-202.

Marks et al., "By-passing immunization. Human antibodies from V-gene libraries displayed on phage," *J. Mol. Biol.* 1991, vol. 222, pp. 581-597.

Merchant et al., "An efficient route to human bispecific IgG," *Nat Biotechnol* 1998, vol. 16, pp. 677-681.

Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," *PNAS* 1984, vol. 81, pp. 6851-6855.

Noren et al., "A general method for site-specific incorporation of unnatural amino acids into proteins," *Science* 1989, vol. 244, p. 182-188.

Ponders and Richards, "Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes," *J. Mol. Biol.*, 1987, vol. 193, pp. 775-791.

Presta, "Antibody engineering," *Curr. Op. Struct. Biol.* 1992, vol. 2, pp. 593-596.

Ridgway, et al., "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization," *Protein Eng.* 1996 vol. 9, No. 7, pp. 617-621.

Riechmann et al., "Reshaping human antibodies for therapy," *Nature* 1988, vol. 332, pp. 323-329.

Schaeffer et al., "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies," *PNAS* 2011, vol. 108, No. 27, pp. 11187-11192.

Werner, R. G., "Appropriate mammalian expression systems for biopharmaceuticals," *Drug Res.* 1998, vo. 48, pp. 870-880.

Wood et al., "High level synthesis of immunoglobulins in Chinese hamster ovary cells," *J. Immunol.* 1990, vol. 145, pp. 3011-3016.

Zhu et al., "Remodeling domain interfaces to enhance heterodimer formation," *Prot. Sci.* 1997, vol. 6, 781-788.

* cited by examiner




FIG. 1


Bi-specific IgM With (A,B)₅ Or (A,B)₆

FIG. 2A




FIG. 2B




FIG. 2C

(A, B) Unit Structural Model




FIG. 3

Constant domains CGL / CE1 / CM1

CE1	ASTQSPSVFPLTECCCKNIPFNATSVTLGCLATGYPEPVMVTCDTGSLNGTT	--MTLPATITLT
CGL	ASTKCPSPVPLAPSSKSTS --GCTAAGCLVKDYFPEPVIVSMNSGALTSGV	--HTFPAVLQSS
	1 10 20 30 40 50 60	
	* * * *	*
CM1	GSASATLPLPLVSCENSPSD -TSSVAVGCLAQDFLPDSITLSNKKYKNNLSSTKCPFSVINGKY	H
	L	
CE1	SGHYATISLLTVSGAWAKQFTCRVANTPSSIDVDNKTIES	
CGL	GLYSLSSVVTVPSS SLGTQTYICNVNKKPSNTKYDKKV	
	70 80 90 100	
	* * *	*
CM1	AATSQVLLPSKXDMQGTDEHVVCVKVQHPNCKNKKKGVPLP	

FIG. 4A

```

Constant domains CE2/CM2

CE2      230      240      250      260      270
      *          *          *
      ssssss      ssssss      ssssss      hhh
VCSRDFTPPVKILQSSCDGGCHFPPTIQLCLVSGYPTPTINITWLEDGQMDVD
      110      130      130      140      150      160
      *          *          *          *
      *          *          *          *
--VIAELPPKVSVPVPRDGFENPEKSLKLCQATGFSPRQIOVSMLEKQVCSGYTDOV

CM2      280      290      300      310      320
      *          *          *          *
      ssssss      sssssssssssssss      ssssss      ssssss
STATTIQEGELASTQSELTLSQKHWSLDRTYTCQVYQQHTELSLKAC
      170      180      190      200      210
      *          *          *          *
QAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDERGLTFQONA      SSMC
      T          S

```

1933 hings

H-53
JEDJLHXSX63

FIG. 4B

Constant domains CG2/CE3/CM3

	330	340	350	360	370	380	*
	*	*	*	*	*	*	*
CE3	-ADSNPRGVSAYLSRPSFDLFI	RRKSP	TI	CLVVDL	APSKGT	VNLSRASGKPVNHSTR	
	240	250	260	270	280	290	
	*	*	*	*	*	*	*
	SSSS	hhhhhh	SSSSSSSS	SSSSSS	SSSSSS	SSSS	
CG2	APELLGQPSVTLFP	PKPKDILMIS	RTPEVTCVV	VDVSHEDPEV	KFNWYVDGVEVHNATK		
	230	240	250	260	270		
	*	*	*	*	*	*	*
CM3	-VPDQTAIRVFAITP	SPASIFLTKSTKL	CLVTLTYD	-SVTISWIRQNGEAVKTHIN			
	G	I	S				
	390	400	410	420	430		
	*	*	*	*	*		
CE3	SSSS	SSSS	SSSS	SSSS	SSSS		
	KEEKORNGTLVT	STLPVGTNDWIE	GEYQCKVTH	PHLPRALMRSTTKTS			
	300	310	320	330	340		
	*	*	*	*	*		
	SSSSSS	hhhhhh	SSSSSS	SSSSSS	SSSS		
CG2	PREEQYNSTYRV	SVTLVLRQDWL	NGKEYCKVSN	KALPAPIEKTLSKAK			
	280	290	300	310	320		
	*	*	*	*	*		
CM3	ISESHPNATYFSA	VGESLCELDWNS	GERFTCTVTH	IDLPSPLKOTISRPK			

FIG. 4C

Contract domains CO / EO / EO / EO

```

440      *      450      *      460      *      470      *      480      *      490      *
*      *      *      *      *      *      *      *      *
SSSSS      SSSSS      SSSSSSSSS      SSSSS      hhh      SSSSS
-GPRAAPEVYAPATPEWQSR -DKRTLACLION FPEDISVQWLHNEVQLPDARHSTTQPBTK
350      360      370      380      390      400
*      *      *      *      *      *
SSSSS      hhhh      SSSSSSSSSSS      SSSSS      SS
-GQREPPQVYTLPPSRDLTK -NOVSLICLVKCFYPSDIAVEMWNSQCPENN      --YKTTTPVILDS
330      340      350      360      370      380      *
*      *      *      *      *      *
GVALHREDVYLLPEAREOLNLRRESATITCLVTCFSPADVFQWMOQOPLSPK      YVTEADMPFEF

```

```

500      510      520      530      540
*      *      *      *      *
ssssssssshhhhhh ssssss ssssss
---GSGPYFSELEVTAEWEQKDEIFCRAVHEAASPSQTVQRAVSVPCK
      410      420      430      440
*      *      *      *
ssssssssshhhhhh ssssss hhhhhsssss
---DGSPLYSKLTVDKSRWQQVPSCSVMHEALHNHYTQSLSLSPCK
      390      400      410      420      430      440
*      *      *      *      *      *
QAPGRYFANS ILTVSEBWNVTCETTYTCVVAHEALENRVTEKSTGKPLXVSLVMSDTAGTCY

```

FIG. 4D

Hetero Monomers




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9

Four CH3 Salt Bridges Stabilize Two Neighbor (A,B) Around Disulphite

Bridge

(A,B) Chain B Chain C (C, D)

K238 ↔ D293
D293 ↔ K238
K268 ↔ D294
D294 ↔ K268

(C,D) Chain D Chain E (E, F)

K238 ↔ D293
D293 ↔ K238
K268 ↔ D294
D294 ↔ K268



FIG. 10

Table A

Human IgM CM4 domain interface residues
Knobs-Holes and charge change positions

Set #1

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
350	T	Y

Hole (CM4 #2): any combination

Residue #	Native Seq	Potential Mutations
352	L	S
393	F	F (W)
395	H	A (V, I, L, S, T)

Set #2 (additions to set #1)

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
354	T	D, E
397	I	D, E

Hole (CM4 #2)

Residue #	Native Seq	Potential Mutations
354	T	K, R
397	I	K, R

Set #3 (additions to set #1)

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
354	T	K, R
397	I	K, R

Hole (CM4 #2)

Residue #	Native Seq	Potential Mutations
354	T	D, E
397	I	D, E

Set #4

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
350	T	Y
395	H	Y

Hole (CM4 #2): any combination

Residue #	Native Seq	Potential Mutations
352	L	S

FIG. 11A

```

393          F          F (W)
395          H          A (V,I,L)
397          I          T (S)
=====
Set #5 (additions to set #4)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T              D,E
397            I              D,E

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T              K,R
397            I              K,R
=====
Set #6 (additions to set #4)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T              K,R
397            I              K,R

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T              D,E
397            I              D,E
=====
Set #7
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
350            T              Y
395            H              F

Hole (CM4 #2): any combination
Residue #      Native Seq      Potential Mutations
350            T              V (A,I,L)
352            L              S
393            F              F (W)
395            H              A (V,I,L)
=====
Set #8 (additions to set #7)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T              D,E
397            I              D,E

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations

```

FIG. 11B

```
354      T      K,R
397      I      K,R
=====
Set #9 (additions to set #7)
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
354         T           K,R
397         I           K,R

Hole (CM4 #2)
Residue #   Native Seq   Potential Mutations
354         T           D,E
397         I           D,E
=====
Set #10
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
350         T           F

Hole (CM4 #2): any combination
Residue #   Native Seq   Potential Mutations
352         L           A
393         F           F (K)
395         K           A (V,I,L,S,T)
=====
Set #11 (additions to set #10)
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
354         T           D,E
397         I           D,E

Hole (CM4 #2)
Residue #   Native Seq   Potential Mutations
354         T           K,R
397         I           K,R
=====
Set #12 (additions to set #10)
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
354         T           K,R
397         I           K,R

Hole (CM4 #2)
Residue #   Native Seq   Potential Mutations
354         T           D,E
397         I           D,E
=====
```

FIG. 11C


```

Set #13
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
350            T              F
395            H              Y

Hole (CM4 #2): any combination
Residue #      Native Seq      Potential Mutations
352            L              A
353            F              F (W)
395            R              A (V, I, L)
397            I              T (S)
=====
Set #14 (additions to set #13)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T              D,E
397            I              D,E

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T              K,R
397            I              K,R
=====
Set #15 (additions to set #13)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T              K,R
397            I              K,R

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T              D,E
397            I              D,E
=====
Set #16
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
350            T              F
395            H              F

Hole (CM4 #2): any combination
Residue #      Native Seq      Potential Mutations
350            T              V (A, I, L)
352            L              A
393            F              F (W)
395            R              A (V, I, L)

```

FIG. 11D

```
*****
Set #17 (additions to set #16)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T               D,E
397            I               U,E

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T               K,R
397            I               K,R
*****
Set #18 (additions to set #16)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T               K,R
397            I               K,R

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T               D,E
397            I               D,E
*****
Set #19
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
350            T               W

Hole (CM4 #2): any combination
Residue #      Native Seq      Potential Mutations
392            L               G (A)
393            F               F (W)
395            H               A (V,S,T)
*****
Set #20 (additions to set #19)
Knob (CM4 #1)
Residue #      Native Seq      Potential Mutations
354            T               D,E
397            I               D,E

Hole (CM4 #2)
Residue #      Native Seq      Potential Mutations
354            T               K,R
397            I               K,R
*****
Set #21 (additions to set #19)
Knob (CM4 #1)
```

FIG. 11E

Residue #	Native Seq	Potential Mutations
354	T	K, R
397	I	K, R

Hole (CM4 #2)

Residue #	Native Seq	Potential Mutations
354	T	D, E
397	I	D, E

Set #22

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
350	T	W
395	H	Y

Hole (CM4 #2): any combination

Residue #	Native Seq	Potential Mutations
352	L	G (A)
393	F	F (W)
395	H	A (V, I, L)
397	I	T (S)

Set #23 (additions to set #22)

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
354	T	D, E
397	I	D, E

Hole (CM4 #2)

Residue #	Native Seq	Potential Mutations
354	T	K, R
397	I	K, R

Set #24 (additions to set #22)

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
354	T	K, R
397	I	K, R

Hole (CM4 #2)

Residue #	Native Seq	Potential Mutations
354	T	D, E
397	I	D, E

Set #25

Knob (CM4 #1)

Residue #	Native Seq	Potential Mutations
-----------	------------	---------------------

FIG. 11F

```
350      T      W
399      H      F

Hole (CM4 #2): any combination
Residue #   Native Seq   Potential Mutations
350         T           V (A,I,L)
352         L           G (A)
393         F           F (W)
395         H           A (V,I,L)
=====
Set #26 (additions to set #25)
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
354         T           D,E
397         I           D,E

Hole (CM4 #2)
Residue #   Native Seq   Potential Mutations
354         T           K,R
397         I           K,R
=====
Set #27 (additions to set #25)
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
354         T           K,R
397         I           K,R

Hole (CM4 #2)
Residue #   Native Seq   Potential Mutations
354         T           D,E
397         I           D,E
=====
Set #28
Knob (CM4 #1)
Residue #   Native Seq   Potential Mutations
334         L           C
350         T           W (F)
395         H           F

Hole (CM4 #2): any combination
Residue #   Native Seq   Potential Mutations
334         L           C
350         T           M
352         L           A (V)
393         F           F (W)
395         H           M (I)
=====
```

FIG. 11G

Set #29 (additions to set #28)
Knob (CM4 #1)
Residue # Native Seq Potential Mutations
354 T D,E
397 I D,E

Hole (CM4 #2)
Residue # Native Seq Potential Mutations
354 T K,R
397 I K,R

=====

Set #30 (additions to set #28)
Knob (CM4 #1)
Residue # Native Seq Potential Mutations
354 T K,R
397 I K,R

Hole (CM4 #2)
Residue # Native Seq Potential Mutations
354 T D,E
397 I D,E

=====

FIG. 11H

Table B

Human IgM CM4 domain interface residues

Potential Charge Swaps in CM4 domain

=====		
Set #1		
CM4 Chain #1		
Residue #	Native Seq	Potential Mutations
326	R	E (D)
CM4 Chain #2		
Residue #	Native Seq	Potential Mutations
339	E	R (K)
=====		
Set #2		
CM4 Chain #1		
Residue #	Native Seq	Potential Mutations
344	R	E (D)
CM4 Chain #2		
Residue #	Native Seq	Potential Mutations
330	D	R (K)
=====		
Set #3		
CM4 Chain #1		
Residue #	Native Seq	Potential Mutations
376	K	E (D)
CM4 Chain #2		
Residue #	Native Seq	Potential Mutations
385	E	R (K)
=====		
Set #4		
CM4 Chain #1		
Residue #	Native Seq	Potential Mutations
427	R	E (D)
CM4 Chain #2		
Residue #	Native Seq	Potential Mutations
339	E	R (K)
=====		

FIG. 12

Table C

Human IgM CM2 domain interface residues
Charge Introductions

Set #1		
CM2 Chain #1		
Residue #	Native Seq	Potential Mutations
116	F	E (D)
133	I	E (D)
CM2 Chain #2		
Residue #	Native Seq	Potential Mutations
116	F	R (K)
133	I	R (K)

FIG. 13

Table D

Human IgM CM2 domain interface residues

Knobs-Holes

Set #1

Knob (CM2 #1)

Residue #	Native Seq	Potential Mutations
119	P	W

Hole (CM2 #2): any combination

Residue #	Native Seq	Potential Mutations
115	V	V (I)
117	V	G (A,S)
132	L	M (A)
189	W	V (I,L,K,F)
210	A	G

Set #2

Knob (CM2 #1)

Residue #	Native Seq	Potential Mutations
116	P	E (D)
119	P	W
133	I	E (D)

Hole (CM2 #2): any combination

Residue #	Native Seq	Potential Mutations
115	V	V (I)
116	F	R (K)
117	V	G (A,S)
132	L	M (A)
133	I	R (K)
189	W	V (I,L,M,F)
210	A	G

Set #3

Knob (CM2 #1)

Residue #	Native Seq	Potential Mutations
116	F	R (K)
119	P	W
133	I	E (K)

Hole (CM2 #2): any combination

Residue #	Native Seq	Potential Mutations
115	V	V (I)
116	F	E (D)
117	V	G (A,S)

FIG. 14A

132	L	M (A)
133	I	E (D)
189	W	V (I, L, M, P)
210	A	G

FIG. 14B

Table E

Human IgM CM2 domain interface residues

Charge Exchanges

Set #1

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
167	E	K (R)

CM2 Chain #2

Residue #	Native Seq	Potential Mutations
177	K	E (D)

Set #2

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
169	K	E (D)

CM2 Chain #2

Residue #	Native Seq	Potential Mutations
170	E	K (R)

Set #3

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
170	E	K (R)

CM2 Chain #2

Residue #	Native Seq	Potential Mutations
177	K	E (D)

Set #4

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
167	E	K (R)
169	K	E (D)

CM2 Chain #2

Residue #	Native Seq	Potential Mutations
170	E	K (R)
177	K	E (D)

FIG. 15

Table 7

Human IgM CM2, CM3 and CM4 domain interface residues
Charge Exchanges

Set #1

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
121	D	K (R)

CM3 Chain #2

Residue #	Native Seq	Potential Mutations
315	K	D (E)

Set #2

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
150	K	E (D)

CM4 Chain #2

Residue #	Native Seq	Potential Mutations
385	E	K (R)

Set #3

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
185	K	E (D)

CM4 Chain #2

Residue #	Native Seq	Potential Mutations
360	D	K (R)

Set #4

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
121	D	K (R)
150	K	E (D)

CM3/CM4 Chain #2

Residue #	Native Seq	Potential Mutations
315	K	D (E)
385	E	K (R)

Set #5

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
121	D	K (R)

FIG. 16A

185 K E (D)

CM3/CM4 Chain #2

Residue #	Native Seq	Potential Mutations
315	K	D (E)
360	D	K (R)

.....

Set #6

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
150	K	E (D)
185	K	E (D)

CM4 Chain #2

Residue #	Native Seq	Potential Mutations
360	D	K (R)
385	E	K (R)

.....

Set #7

CM2 Chain #1

Residue #	Native Seq	Potential Mutations
121	D	K (R)
150	K	E (D)
185	K	E (D)

CM3/CM4 Chain #2

Residue #	Native Seq	Potential Mutations
315	K	D (E)
360	D	K (R)
385	E	K (R)

.....

FIG. 16B

CONSTANT CHAIN MODIFIED BISPECIFIC, PENTA- AND HEXAVALENT IG-M ANTIBODIES

This application is a national stage application filed under 35 USC § 371 of PCT Application No. PCT/US2014/054079, filed Sep. 4, 2014, which claims the benefit of priority under 35 USC § 119(e) of provisional application Nos. 61/874,277, filed Sep. 5, 2013 and 61/874,284, filed Sep. 5, 2013, the entire contents of each application are incorporated herein by reference.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 5, 2018, is named IGM-0001-2-US_SL_Substitute_ST25.txt and is 86,421 bytes in size.

FIELD OF THE INVENTION

The present invention concerns binding molecules with penta- or hexameric structure.

In particular, the invention relates to binding molecules having a penta- or hexameric ring structure comprising five or six bispecific binding units. In the binding molecules of the present invention each of the bispecific binding units binds two different binding targets or different binding regions (e.g. epitopes) on the same binding target, and each of the five or six bispecific binding units have the same binding specificities (bind to the same two binding targets). In a particular embodiment, the invention concerns bispecific antibodies with penta- or hexameric structure, comprising five or six bispecific binding units.

In a different aspect, the invention includes binding molecules comprising five or six monospecific binding units, where (i) each of the monospecific binding units comprises two IgM heavy chain constant regions each comprising at least a C_μ3 and C_μ4 domain conjugated to a binding region to a binding target, (ii) at least two of the monospecific binding units bind to different binding target. The invention further includes binding molecules comprising five or six bispecific binding units, where (i) each of the bispecific binding units comprises two IgM heavy chain constant regions each comprising at least a C_μ3 and C_μ4 domain conjugated to a binding region to a binding target, and (ii) at least two of the bispecific binding units bind to different binding targets. In a particular embodiment, the binding molecules are multi-specific IgM antibodies.

BACKGROUND OF THE INVENTION

Since the advent of humanized antibodies, the therapeutic use of antibodies such as Rituxan® (rituximab), Herceptin® (trastuzumab) and Avastin® (bevacizumab), has revolutionized the fields of medicine, including oncology, the treatment of inflammatory disorders, such as rheumatoid arthritis, and many other indications. In the United States, more than 30 human or humanized antibodies have been approved for clinical use, and more than 600 new antibodies or antibody-like molecules are in various stages of development. Some antibodies have antagonistic function on soluble target molecules such as vascular endothelial growth factor (VEGF) or tumor necrosis factor (TNF), whose actions are part of the pathologic process of a disease. Alternatively,

antibodies can bind, block and/or induce destruction of pathologic cells in certain diseases, such as cancer. The main functions of these therapeutic antibodies are binding through the Fab region, and recruitment of effector function via the Fc domain (which also mediates the long circulating half-life of antibodies). One of the major advantages of antibodies compared to small molecule drugs, can be their exquisite specificity. Antibodies can very accurately target selected protein antigens, such as oncogenes, to the exclusion of very similar homologs, allowing for benign safety profiles. Hence, antibodies are well characterized for specific single targeting function.

As the field has progressed, antibody function has been enhanced through creative means of protein engineering, such as to provide higher affinity, longer half-life, and/or better tissue distribution, as well as combination of small and large molecule technologies for increased focus of cell destruction via toxic payload delivery (e.g. antibody-drug conjugates). Another approach to improving antibody function takes advantage of the bivalent binding of the immunoglobulin G (IgG) structure which allows one IgG molecule to bind two antigens. Indeed, in certain applications, there exists good potential for asymmetric antibodies to exert useful functions by simultaneously binding two different target antigens. To address this need, a variety of constructs have been produced to yield a single molecule that can bind two different antigens, allowing for functions never before seen in nature. An example of this bi-specific approach is "blinatumumab" (MT103) which binds the CD3 and CD19 receptors, on T- and B-cells, respectively. This tethering of a cytotoxic T cell to a cancerous B-cell, allows for effective treatment of B-cell leukemia.

However, there remain significant technical difficulties in construction, expression and production of bispecific antibodies. Although bispecific antibodies are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens, their utility is limited due to problems with stability and manufacturing complexity.

Various forms of protein engineering have been used to match heterologous heavy chains, plus appropriate pairwise matching of heavy and light chains to efficiently yield a bi-specific IgG. In addition, various bispecific antibody formats, including quadromas, chemical heteroconjugates, recombinant constructs using selected heterodimerization domains and recombinant constructs of minimal size consisting of two minimal antigen-binding sites.

However, all of these efforts have been fraught with difficulty.

Thus, despite efforts directed toward the development of bispecific therapeutic antibodies, there remains a great need for developing more efficient platforms that can lead to more efficient and flexible production of bi- and multispecific antibodies, thereby shortening the timeline between discovery and clinical introduction of such therapeutics and enabling the design and production of new types of antibody formats with multiple specificities and/or valencies.

SUMMARY OF THE INVENTION

The present invention concerns binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same.

In one aspect, the invention concerns a binding molecule having a penta- or hexameric ring structure comprising five or six bispecific binding units, wherein each of the bispecific

3

binding units has the same two binding specificities and comprises a first chain comprising at least a C μ 4 domain of an IgM heavy chain constant region conjugated to a first binding region to a first binding target, and a second chain comprising at least a C μ 4 domain of an IgM heavy chain constant region and a second binding region to a second binding target, wherein the first and second binding targets are different, and wherein the first and second chains are assembled to create a bispecific binding unit as a result of an asymmetric interface created between their respective IgM heavy chain constant regions.

In one embodiment, the bispecific binding units are identical.

In another embodiment, the binding molecule further comprises an IgM J chain.

In yet another embodiment, the binding molecule has a pentameric ring structure.

In a further embodiment, the binding molecule has a hexameric ring structure.

In a still further embodiment, in the binding molecule the first and the second chains further comprise a C μ 3 domain of an IgM heavy chain constant region.

In another embodiment, the first and second chains further comprise a C μ 2 domain of an IgM heavy chain constant region.

In other embodiments, the first and second binding targets are selected from peptides, polypeptides, glycoproteins, nucleic acid molecules, and organic and non-organic small molecules, including, without limitation, soluble polypeptides, cell surface receptors, ligands, molecular transporters, enzymes and substrates of enzymes.

In a still further embodiment, the first and second binding targets are two sites on the same soluble target, two sites on the same cell surface receptor target, two different soluble targets, two cell surface receptor targets, one soluble target and one cell surface receptor target, one soluble or cell surface receptor target and one long residence time target, one soluble target and one matrix protein or substrate target, one soluble or receptor target and one molecular transporter target, or two different cell types.

The conjugation of the binding regions to the rest of the molecule may take place by fusion. Thus, for example, the first and second binding regions may be fused to the N-termini of the first and second IgM heavy chain constant regions, respectively.

In a particular embodiment, the first and second binding regions are variable regions of an antibody.

In another embodiment, the first and second binding targets are two different antigens.

In yet another embodiment, the first and second binding targets are different epitopes on the same antigen.

In further embodiments, the first and second binding regions may be two different antibody heavy chain variable regions, binding to two binding targets, or to different epitopes on the same binding target.

In the binding molecules of the present invention the antibody heavy chain variable regions may be from an IgG, IgA, IgE, and/or IgM antibody, preferably from an IgM antibody. Preferably, the binding molecules herein are bispecific IgM molecules, which may, but are not required to, further comprise at least one IgM light chain variable region sequence associated with one of two different IgM heavy chain variable regions.

In a particular embodiment, in the binding molecules of the present invention at least some of the asymmetric interfaces between the IgM heavy chain constant regions of the two chains of a binding unit are created by a salt bridge

4

formed by pair-wise switches between oppositely charged amino acid residues in at least one of the C μ 2, C μ 3 and/or C μ 4 domains of the two chains of said binding unit.

Thus, a salt bridge may be formed between at least one of the C μ 2-C μ 2, C μ 4-C μ 4, and C μ 2-C μ 3-C μ 4 domains of the two chains of a binding unit.

In one embodiment, the pair-wise switches are selected from the group consisting of E $\rightarrow$ K, K $\rightarrow$ E; R $\rightarrow$ E, E $\rightarrow$ R; D $\rightarrow$ K, K $\rightarrow$ D; and R $\rightarrow$ D, D $\rightarrow$ R.

In another embodiment, the binding molecule may comprise at least one pair-wise charged amino acid residue switch in the C μ 4-C μ 4 domains, where the switch may, for example, be selected from the group consisting of R328F, D $\leftrightarrow$ E339R,K; R344E,D $\leftrightarrow$ S330R,K; K376E,D $\leftrightarrow$ E385R,K; R427E,D $\leftrightarrow$ E339R,K; and T354E,D $\leftrightarrow$ I397R,K, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In a further embodiment, at least one pair-wise charged amino acid switch between the C μ 2-C μ 2 domains, and may, for example, be selected from the group consisting of E167R,K $\leftrightarrow$ K177E,D and K169E,D $\leftrightarrow$ E170R,K, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In a still further embodiment, at least one pair-wise charged amino acid residue switch is in the C μ 2-C μ 3-C μ 4 domains, and may, for example, be selected from the group consisting of D121K,R $\leftrightarrow$ K315D,E; K150E,D $\leftrightarrow$ E385R,K; and K185D,E $\leftrightarrow$ D360K,R, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In a further embodiment, in the binding molecules of the present invention at least some of the asymmetric interfaces between the IgM heavy chain constant regions of the two chains of a binding unit are created through knobs-into-holes connections, which may, for example, be created by mutations selected from the group consisting of knobs: T350 $\rightarrow$ Y, F,W; and I1395 $\rightarrow$ Y,F; and holes: L352 $\rightarrow$ G,A,V,I,M,S,T; H395 $\rightarrow$ A,V,I,L,M,F,Y; F393 $\rightarrow$ W,Y; I397 $\rightarrow$ A,V,S,T; T350 $\rightarrow$ S,A,V; and T348 $\rightarrow$ S, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In a specific embodiment, in the binding molecules of the present invention the light chain variable region sequences, if present, are coupled to their matching heavy chain variable region by creating an asymmetric interface between the light and heavy chains.

In other embodiments, the asymmetric interface is created by CrossMab technique, knobs-into-holes coupling and/or salt bridges coupling.

The binding molecules of the present invention might comprise a common light chain and/or might be conjugated to a toxin or a chemotherapeutic agent. Preferably, conjugation is by fusion, but conjugation by a chemical linker is also included within the scope of the invention.

The binding molecules herein might be bispecific antibodies with a penta- or hexameric structure, which might be chimeric or humanized.

In a different aspect, the invention concerns a composition comprising at least about 70%, or at least 80%, or at least 90% or at least 95%, or at least 98%, or at least 99% of the binding molecule as hereinabove defined.

In a particular embodiment, the composition is a pharmaceutical composition.

The present invention further concerns a multi-specific binding molecule having a penta- or hexameric ring structure comprising five or six monospecific binding units, wherein (i) each of the monospecific binding units com-

prises two IgM heavy chain constant regions each comprising at least a C μ 3 and C μ 4 domain conjugated to a binding region to a binding target, (ii) at least two of the monospecific binding units bind to different binding targets, and (iii) an external asymmetric interface is created between the heavy chain constant regions of the neighboring monospecific binding units that bind to different binding targets.

In one embodiment, at least three of the monospecific binding units bind to different binding targets.

In another embodiment, at least four of said monospecific binding units bind to different binding targets.

In yet another embodiment, the binding molecule has a pentameric ring structure and all five monospecific binding units bind to different targets.

In a further embodiment, the binding molecule has a hexameric ring structure and at least five of said monospecific binding units bind to different targets.

In a still further embodiment, all six of the monospecific binding units bind to different targets.

In another aspect, the invention concerns a multi-specific binding molecule having a penta- or hexameric ring structure comprising five or six bispecific binding units, where (i) each of the bispecific binding units comprises two IgM heavy chain constant regions each comprising at least a C μ 3 and C μ 4 domain conjugated to a binding region to a binding target, (ii) at least two of the bispecific binding units bind to different binding targets, (iii) an internal asymmetric interface is created between two IgM heavy chain constant regions of each bispecific binding unit, and (iv) an external asymmetric interface is created between the heavy chain constant regions of the neighboring bispecific binding units binding to different targets.

In one embodiment, at least three of the bispecific binding units bind to different binding targets.

In another embodiment, at least four of the bispecific binding units bind to different binding targets.

In yet another embodiment, the binding molecule has a pentameric ring structure and all five bispecific binding units bind to different targets.

In a further embodiment, the binding molecule has a hexameric ring structure and at least five of the bispecific binding units bind to different targets.

In a still further embodiment, all six bispecific binding units bind to different targets.

In a different embodiment, the multi-specific binding molecule further comprises an IgM J chain.

In various embodiments, the multi-specific binding molecule may have a pentameric or hexameric ring structure.

Regardless of the number and nature of the binding specificities of the multi-specific binding molecules of the present invention, the following specific embodiments apply:

In one embodiment, in at least one of the binding units the IgM heavy chain constant regions further comprise a C μ 2 domain. In yet another embodiment, in all of the binding units the IgM heavy chain constant regions further comprise a C μ 2 domain. In various embodiments, the multi-specific binding molecules of the present invention may bind to binding targets selected from peptides, polypeptides, glycoproteins, nucleic acid molecules, and organic and non-organic small molecules.

In other embodiments, the multi-specific binding molecules of the present invention bind to binding targets selected from soluble polypeptides, cell surface receptors, ligands, molecular transporters, enzymes and substrates of enzymes.

In further embodiments, the multi-specific binding molecules of the present invention binding to different targets are selected from the group consisting of binding units binding to sites on the same soluble target; sites on the same cell surface receptor target; different soluble targets; different cell surface receptor targets; soluble and cell surface receptor targets; soluble or cell surface receptor and long residence time targets; soluble and matrix protein or substrate targets; soluble or receptor and molecular transporter targets, and different cell types.

In a particular embodiment, in the binding units within the binding molecules of the present invention the conjugation between the IgM heavy chain constant regions and the binding region to a binding target is by fusion. Thus, for example, the binding regions may be fused to the N-termini of the IgM heavy chain constant regions.

In one embodiment, at least one of the binding regions is a variable region of an antibody.

In another embodiment, all of the binding regions are antibody heavy chain variable regions.

In yet another embodiment, at least two binding targets are different antigens.

In a further embodiment, at least two binding targets are different epitopes on the same antigen.

In all aspects and embodiments, the antibody heavy chain variable regions may be from an IgG, IgA, IgE, or IgM antibody, preferably from an IgM antibody.

In a preferred embodiment, the multi-specific binding molecule of the present invention is a multi-specific IgM antibody.

In one embodiment, the multi-specific IgM antibody of the present invention further comprises at least one IgM light chain variable region sequence associated with an IgM heavy chain variable region in at least one of the binding units.

In another embodiment, the multi-specific IgM antibody further comprises an IgM light chain variable region sequence associated with each of the IgM heavy chain variable regions.

In all aspects and embodiments, the external asymmetric interface is created by alteration(s) within the C μ 3 domain. In one embodiment, the alteration is created by a salt bridge formed by pair-wise switches between oppositely charged amino acid residues in the C μ 3 domain.

In various embodiments, the salt bridge providing the external asymmetric interface is formed by at least one pair-wise charged amino acid residue switch in the C μ 3-C μ 3 domains, which may, for example be K238 $\leftrightarrow$ D293 or K268 $\leftrightarrow$ D294 in the neighboring μ chains, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In all aspects and embodiments, in the multi-specific binding molecules, e.g. multi-specific IgM antibodies, of the present invention the internal asymmetric interfaces are created by a salt bridge formed by pair-wise switches between oppositely charged amino acid residues in at least one of the C μ 2, C μ 3 and/or C μ 4 domains.

In one embodiment, a salt bridge is formed between at least one of the C μ 2-C μ 2, C μ 4-C μ 4, and C μ 2-C μ 3-C μ 4 domains of the two chains of said binding unit.

In another embodiment, the pair-wise switches are selected from the group consisting of E $\rightarrow$ K, K $\rightarrow$ E; R $\rightarrow$ E, E $\rightarrow$ R; D $\rightarrow$ K, K $\rightarrow$ D; and R $\rightarrow$ D, D $\rightarrow$ R.

In a further embodiment, the multi-specific binding molecule, e.g. multi-specific IgM antibody, comprises at least one pair-wise charged amino acid residue switch in the C μ 4-C μ 4 domains, which may, for example be selected from

the group consisting of R328E,D↔E339R,K; R344E,D↔S330R,K; K376E,D↔E385R,K; R427E,D↔E339R,K; and T354E,D↔I397R,K, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In a still further embodiment, the multi-specific binding molecule, e.g. multi-specific IgM antibody, comprises at least one pair-wise charged amino acid switch between the C μ 2-C μ 2 domains, which may, for example, be selected from the group consisting of E167R,K↔K177E,D and K169E,D↔E170R,K, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In another embodiment, the multi-specific binding molecule, e.g. multi-specific IgM antibody, comprises at least one pair-wise charged amino acid residue switch in the C μ 2-C μ 3-C μ 4 domains, which may, for example, be selected from the group consisting of D121K,R↔K315D,E; K150E,D↔E385K,R; and K185D,E↔D360K,R, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In all aspects and embodiments, at least some of the external and/or internal asymmetric interfaces between the IgM heavy chain constant regions may be created through knobs-into-holes connections. For example, at least one knobs-into-hole connection may be created by mutations selected from the group consisting of knobs: T350→Y,F,W; and H395→Y,F; and holes: L352→G,A,V,I,M,S,T; H395→A,V,I,L,M,F,Y; F393→W,Y; I397→A,V,S,T; T350→S,A,V; and T348→S, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

In the multi-specific IgM antibodies comprising a light chain variable region sequence, such light chain variable region sequences may be coupled to their matching heavy chain variable regions by creating an asymmetric interface between the light and heavy chains. In various embodiments, the asymmetric interface may be created by Cross-Mab technique, knobs-into-holes coupling and/or salt bridges coupling. In a further embodiment, the binding units of the multi-specific binding molecule comprise a common light chain.

In all aspects and embodiments, the multi-specific binding molecule may be conjugated to a toxin or a chemotherapeutic agent, where the conjugation may, for example, be by fusion and/or through a chemical linker.

The multi-specific IgM antibodies of the present invention may be chimeric or humanized.

In a further aspect, the invention concerns a composition comprising at least about 70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 98%, or at least about 99% of a multi-specific binding molecule herein. The composition may, for example, be a pharmaceutical composition, comprising at least one pharmaceutically acceptable ingredient.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the structure of an IgM pentamer, comprising a J chain, wherein chains A and B are identical in native IgM.

FIG. 2A illustrates a five-membered IgM molecule with two binding specificities, where the heavy (μ) chains designated as A and B are different.

FIG. 2B illustrates a multi-specific IgM antibody comprising five or six monospecific binding units, where (i) each of the monospecific binding units comprises two IgM heavy

chain constant regions each comprising at least a C μ 4 domain conjugated to a binding region to a binding target, (ii) at least two of the monospecific binding units bind to different binding target.

FIG. 2C illustrates a multi-specific IgM antibody comprising five or six bispecific binding units, where (i) each of the bispecific binding units comprises two IgM heavy chain constant regions each comprising at least a C μ 4 domain conjugated to a binding region to a binding target, and (ii) at least two of the bispecific binding units bind to different binding targets.

FIG. 3 is a structural model of the A and B heavy chains of an IgM molecule as published in Czajkowsky D. M, Shao Z, PNAS 2009; 106:14960-14965.

FIG. 4A shows the alignment of the CG1 (SEQ ID NO: 20), CE1 (SEQ ID NO: 19) and CM1 (SEQ ID NO: 21) constant domains of human IgG1, IgE and IgM, respectively.

FIG. 4B shows the alignment of the CE2 (SEQ ID NO: 22) and CM2 (SEQ ID NO: 23) constant domains of human IgE and IgM, respectively. CG-H is disclosed as SEQ ID NO: 24.

FIG. 4C shows the alignment of the CG2 (SEQ ID NO: 26), CE3 (SEQ ID NO: 25) and CM3 (SEQ ID NO: 27) constant domains of human IgG1, IgE and IgM, respectively.

FIG. 4D shows the alignment of the CG3 (SEQ ID NO: 29), CE4 (SEQ ID NO: 28) and CM4 (SEQ ID NO: 30) constant domains of human IgG, IgE and IgM, respectively.

The complete sequential IgF constant region sequence as shown in FIGS. 4A-4D (SEQ ID Nos 19, 22, 25, and 28) is presented as SEQ ID NO: 31. The complete sequential IgG constant region sequence as shown in FIGS. 4A-4D (SEQ ID Nos 20, 24, 26, and 29) is presented as SEQ ID NO: 32. The complete sequential IgM constant region sequence as shown in FIGS. 4A-4D (SEQ ID Nos 21, 23, 27, and 30) is presented as SEQ ID NO: 33.

In FIGS. 4A-4D:

human IgF sequence (SEQ ID NO: 31) is encoded by GenBank J00222.1 (replaced by AH005273.2); residue numbering from PDB 2WQR; helix (h) and sheet (s) assignments from PDB 2WQR;

human IgG1 (SEQ ID NO: 32) sequence is encoded by GenBank J00228.1 (replaced by AH007035.2); residue numbering from PDB 1OQO; helix (h) and sheet (s) assignments from PDB 1OQO;

human IgM sequence (SEQ ID NO: 33) is encoded by GenBank X14940.1; residue numbering is sequential from start of CM1 domain; reported variance in human IgM sequences noted below IgM sequence for GenBank CAB37838.1, CAC20458.1, AFM37312.1, X57331.1 and J00260.1.

FIG. 5 shows the structure of hetero-monomers prepared in Example 1.

FIG. 6 shows a non-reduced SDS-PAGE gel of wild-type and engineered IgM Fc pairs 2a and 2b.

Lane 1: wild-type Rtx:Fc.

Lane 2: a mixture of Rtx2a:Fc2b, where Rtx2a is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human μ chain with C291S, T350Y, T354E, and I397E mutations and tail piece deletion; and Fc2b is human μ chain CH2 to CH4 and with C291S, L352S, T354K, I1395V, and I397K mutations and tail piece deletion, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

Lane 3: a mixture of Rtx2b:Fc2a, where Rtx2b is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human mu chain with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion; and Fc2a consists of a human μ chain CH2 to CH4 region with C291S, T350Y, T354E, and I397E mutations and tail piece deletion, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33. Arrow indicates heterodimer.

FIG. 7 shows a reduced SDS-PAGE gel of wild-type and engineered IgM Fc pairs 1a and 2b, where the designations are the same as in FIG. 6.

FIG. 8 shows a non-reduced SDS-PAGE gel of wild-type and engineered IgM Fc pairs:

Lane 1: wild-type Okt:Fc. Okt, composed of OKT3 (anti-CD3 antibody) scFv fused with CM2 to CM4 of human μ chain.

Lane 2: a mixture of Okt2a:Fc2b, where Okt2a is composed of OKT3 (anti-CD3 antibody) scFv fused with CM2 to CM4 of human μ chain with C291S, T350Y, T354E, and I397E mutations and tail piece deletion, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33;

Lane 3: a mixture of Okt2b:Fc2a, where Okt2b is composed of OKT3 (anti-CD3 antibody) scFv fused with CM2 to CM4 of human μ chain with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33. Arrow indicates heterodimer.

Lanes 4-6: Wild-type Okt:Rtx combination; engineered Okt2a:Rtx2b combination; and Okt2b:Rtx2a combination, where Rtx2a is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human μ chain with C291S, T350Y, T354E, and I397E mutations and tail piece deletion, and Rtx2b is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human mu chain with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33. Arrow indicates the heterodimer.

FIG. 9 shows reduced samples on SDS-PAGE gel of 293F cell transfectants of the same constructs as shown in FIG. 8.

FIG. 10 illustrates how four salt bridges in the C μ 3 region stabilize two neighboring (A,B) μ chains around a disulfide bridge in a multi-specific binding molecule of the present invention.

FIGS. 11A-11H (Table A) list human IgM CM4 domain interface residues in knobs-holes positions and for potential charge introductions. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

FIG. 12 (Table B) list human IgM CM4 domain interface residues for potential charge swaps. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

FIG. 13 (Table C) list human IgM CM2 domain interface residues for potential charge introductions. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

FIGS. 14A-14B (Table D) list human IgM CM2 domain interface residues in knobs-holes positions. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

FIG. 15 (Table E) list human IgM CM2 domain interface residues for potential charge swaps. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

FIG. 16A-16B (Table F) list human IgM CM2, CM3 and CM4 domain interface residues for charge exchanges. The amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

The term "antibody" includes monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab')₂, and Fv). The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein. The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains.

In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (V_H) followed by three constant domains (C_H) for each of the α and γ chains and four C_H domains for μ and ϵ isotypes. Each L chain has at the N-terminus, a variable domain (V_L) followed by a constant domain at its other end. The V_L is aligned with the V_H and the C_L is aligned with the first constant domain of the heavy chain (C_{H1}). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a V_H and V_L together forms a single antigen-binding site.

IgM forms polymers where multiple immunoglobulins are covalently linked together with disulfide bonds. IgM mostly exists as a pentamer but also as a hexamer and therefore contains 10 or 12 antigen binding sites. The pentameric form optionally contains an additional polypeptide, called the J chain, but can also be made in the absence of J chain. The pentameric IgM molecule has a molecular weight of approximately 970 kDa. Due to its polymeric nature, IgM possesses high avidity and is particularly effective in complement activation. Unlike in IgG, the heavy chain in IgM monomers is composed of one variable and four constant domains. The IgM constant domains are designated herein as CM1 or C μ 1, CM2 or C μ 2, CM3 or C μ 3, and CM4 or C μ 4, wherein the "CM" and C μ designations are used interchangeably.

IgA antibodies exist in a monomeric form but can also polymerize. In their secretory form IgA comprise from 2-5 of the basic 4-chain units linked by a J chain and a secretory component.

IgE exists in monomeric form, and has four constant domains, which are referred to as CE1, CE2, CE3 and CE4 in the present application.

The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains.

Some types of antibodies can further be divided into various sub-classes: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.

For further details of the structure and properties of the different classes of antibodies, see e.g., Basic and Clinical Immunology, 8th Edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds), Appleton & Lange, Norwalk, Conn., 1994, page 71 and Chapter 6.

Unless stated otherwise, the term "antibody" specifically includes native human and non-human IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD and IgM antibodies, including naturally occurring variants. Thus, for example, the human IgM sequence presented as SEQ ID NO: 33 is encoded by the genomic sequence available under GenBank Accession Number X14940.1 (variant nucleotide sequences available under GenBank Accession Numbers X57331.1, and J00260.1 (replaced by AH005277.2)), while amino acid variants have been reported as GenBank CAB37838.1, CAC20458.1, and AFM37312.1.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) *Nature* 256:495, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) *Nature* 352:624-628 and Marks et al. (1991) *J. Mol. Biol.* 222:581-597, for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855).

"Humanized" forms of non-human (e.g., murine) antibodies are antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are also replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the

humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al. (1986) *Nature* 321:522-525; Riechmann et al. (1988) *Nature* 332:323-329; and Presta (1992) *Curr. Op. Struct. Biol.* 2:593-596.

A "species-dependent antibody" is one which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species. Normally, the species-dependent antibody "binds specifically" to a human antigen (i.e. has a binding affinity (K_d) value of no more than about 1×10^{-7} M, preferably no more than about 1×10^{-8} M and most preferably no more than about 1×10^{-9} M) but has a binding affinity for a homologue of the antigen from a second nonhuman mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen. The species-dependent antibody can be any of the various types of antibodies as defined above, but preferably is a humanized or human antibody.

As used herein, "antibody mutant" or "antibody variant" refers to an amino acid sequence variant of a reference antibody wherein one or more of the amino acid residues of the reference antibody have been modified. The reference antibody can, for example, be a native antibody but also a known variant of a native antibody. Such mutants necessarily have less than 100% sequence identity or similarity with the reference antibody. In a preferred embodiment, the antibody mutant will have an amino acid sequence having at least 75% amino acid sequence identity or similarity with the amino acid sequence of either the heavy or light chain variable domain of the reference antibody, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e. same residue) or similar (i.e. amino acid residue from the same group based on common side-chain properties) with the reference antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence outside of the variable domain shall be construed as affecting sequence identity or similarity.

An "isolated" bispecific or multi-specific binding molecule, such as bispecific or multi-specific antibody, herein is one which has been identified and separated and/or recovered from a component of its natural environment in a recombinant host cell. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the molecule, e.g. antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes, as well as undesired byproducts of the production, such as, for example, monospecific binding units (AA and/or BB in the case of a bispecific molecule comprising AB binding units), or molecules, with less than five bispecific binding units. In preferred embodiments, the bispecific binding molecule, such as antibody, will be purified (1) to greater than 95% by weight, or greater than 98% by weight, or greater than 99%

by weight, as determined by SDS-PAGE or SEC-HPLC methods, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of an amino acid sequencer, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. Ordinarily, an isolated multi-specific, e.g. bispecific binding molecule, e.g. antibody, will be prepared by at least one purification step.

The term "specific binding" or "specifically binds to" or is "specific for" refers to the binding of a binding molecule, such as an antibody, to a target molecule, e.g., a particular polypeptide or an epitope on a particular polypeptide, peptide, or other target (e.g. a glycoprotein target), and means binding that is measurably different from a non-specific interaction (e.g., a non-specific interaction may be binding to bovine serum albumin or casein). Specific binding can be measured, for example, by determining binding of antibody to a target molecule compared to binding of antibody to a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a Kd for the target of at least about 200 nM, alternatively at least about 150 nM, alternatively at least about 100 nM, alternatively at least about 60 nM, alternatively at least about 50 nM, alternatively at least about 40 nM, alternatively at least about 30 nM, alternatively at least about 20 nM, alternatively at least about 10 nM, alternatively at least about 8 nM, alternatively at least about 6 nM, alternatively at least about 4 nM, alternatively at least about 2 nM, alternatively at least about 1 nM, or greater. In certain instances, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

"Binding affinity" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). For example, the Kd can be about 200 nM, 150 nM, 100 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 8 nM, 6 nM, 4 nM, 2 nM, 1 nM, or stronger. Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known in the art.

As used herein, the "Kd" or "Kd value" refers to a dissociation constant measured by a technique appropriate for the antibody and target pair, for example using surface plasmon resonance assays, for example, using a BIAcore™-2000 or a BIAcore™-3000 (BIAcore, Inc., Piscataway, N.J.) at 25° C. with immobilized antigen CM5 chips at about 10 response units (RU).

The term "bispecific binding unit" is used herein to refer to a molecule comprising a pair of IgM heavy chain constant

region polypeptides each comprising at least a CM4 domain, and each conjugated to a binding region to a different binding target. Preferably, the conjugation is by fusion, preferably to the N-terminus of the IgM heavy chain constant region polypeptide sequence. The term "bispecific binding unit" specifically encompasses, but is not limited to, a "bispecific IgM antibody binding unit," as hereinafter defined. The binding molecules of the present invention have a penta- or hexameric ring structure and comprise five or six bispecific binding units.

The terms "conjugate," "conjugated," and "conjugation" refer to any and all forms of covalent or non-covalent linkage, and include, without limitation, direct genetic or chemical fusion, coupling through a linker or a cross-linking agent, and non-covalent association.

The term "bispecific IgM antibody binding unit" is used in the broadest sense and specifically covers a pair of IgM antibody heavy chain constant region polypeptides, comprising at least a CM4 constant domain, fused to a variable domain sequence (V_H), each variable domain sequence binding to a different target, with or without associated antibody light chain variable domain (V_L) sequences. In one embodiment, the bispecific IgM antibody comprises two V_HV_L antigen binding regions, each capable of binding to a different epitope on one antigen or epitopes on two different antigens. The bispecific IgM antibody binding units can be full length from a single species, or be chimerized or humanized. The bispecific IgM antibodies of the present invention have a penta- or hexameric ring structure comprising five or six bispecific IgM binding units.

A "full length IgM antibody heavy chain" is a polypeptide consisting in N-terminal to C-terminal direction of an antibody heavy chain variable domain (VH), an antibody constant heavy chain constant domain 1 (CM1 or Cμ1), an antibody heavy chain constant domain 2 (CM2 or Cμ2), an antibody heavy chain constant domain 3 (CM3 or Cμ3), and an antibody heavy chain constant domain 4 (CM4 or Cμ4). The bispecific full length IgM antibodies according to the invention comprise five or six monomers (binding units), each with two antigen binding sites, which specifically bind to two different binding targets (epitopes). The C-terminus of the heavy or light chain of the full length antibody denotes the last amino acid at the C-terminus of the heavy or light chain. The N-terminus of the heavy or light chain of the full length antibody denotes the first amino acid at the N-terminus of the heavy or light chain.

The term "valent" as used herein denotes the presence of a specified number of binding sites in an antibody. As such, the terms "bivalent", "tetravalent", and "hexavalent" denote the presence of two binding sites, four binding sites, and six binding sites, respectively. In the bispecific IgM antibodies according to the invention each binding unit is bivalent. Accordingly, the bispecific IgM antibodies herein have 10 or 12 valencies. The definition similarly applies to binding molecules that are non-antibodies.

The term "epitope" includes any molecular determinant capable of specific binding to an antibody. In certain embodiments, epitope determinant include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody. A "binding region" is a region on a target bound by a binding molecule.

"Polyepitopic specificity" refers to the ability to specifically bind to two or more different epitopes on the same or

different target(s). "Monospecific" refers to the ability to bind only one epitope. According to one embodiment the bispecific IgM antibody binds to each epitope with an affinity of at least 10^{-7} M, or 10^{-8} M or better.

The term "target" is used in the broadest sense and specifically includes polypeptides, nucleic acids, carbohydrates, lipids, and other molecules with biological function as they exist in nature. The "target" may, for example, be a cell, wherein the bispecific binding units target two different cell types, different subpopulations of the same cell type (e.g. different B-cell populations) or two different entities on a single cell.

An "antigen-binding site" or "antigen-binding region" of an antibody of the present invention typically contains six complementarity determining regions (CDRs) which contribute in varying degrees to the affinity of the binding site for antigen. There are three heavy chain variable domain CDRs (CDRH1, CDRH2 and CDRH3) and three light chain variable domain CDRs (CDRL1, CDRL2 and CDRL3). The extent of CDR and framework regions (FRs) is determined by comparison to a compiled database of amino acid sequences in which those regions have been defined according to variability among the sequences and/or structural information from antibody/antigen complexes. Also included within the scope of the invention are functional antigen binding sites comprised of fewer CDRs (i.e., where binding specificity is determined by three, four or five CDRs). Less than a complete set of 6 CDRs may be sufficient for binding to some binding targets. Thus, in some instances, the CDRs of a VH or a VL domain alone will be sufficient. Furthermore, certain antibodies might have non-CDR-associated binding sites for an antigen. Such binding sites are specifically included within the present definition.

The term "interface", as used herein, is used to refer to a region, which comprises those "contact" amino acid residues (or other non-amino acid groups such as, for example, carbohydrate groups,) in a first IgM heavy chain constant region which interact with one or more "contact" amino acid residues (or other non-amino acid groups) in a second IgM heavy chain constant region.

The term "asymmetric interface" is used to refer to an interface (as hereinabove defined) formed between two antibody chains, such as a first and a second IgM heavy chain constant region and/or between an IgM heavy chain constant region and its matching light chain, wherein the contact residues in the first and the second chains are different by design, comprising complementary contact residues. The asymmetric interface can be created by knobs/holes interactions and/or salt bridges coupling (charge swaps) and/or other techniques known in the art, such as for example, by the CrossMab approach for coupling a μ heavy chain to its matching light chain.

A "cavity" or "hole" refers to at least one amino acid side chain which is recessed from the interface of the second polypeptide and therefore accommodates a corresponding protuberance ("knob") on the adjacent interface of the first polypeptide. The cavity (hole) may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the second polypeptide is altered to encode the cavity. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one "import" amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the

number of original residues which are replaced is the total number of residues in the interface of the second polypeptide. The preferred import residues for the formation of a cavity are usually naturally occurring amino acid residues and are preferably selected from alanine (A), serine (S), threonine (T), valine (V) and glycine (G). Most preferred amino acid residues are serine, alanine or threonine, most preferably alanine. In the preferred embodiment, the original residue for the formation of the protuberance has a large side chain volume, such as tyrosine (Y), arginine (R), phenylalanine (F) or tryptophan (W).

An "original" amino acid residue is one which is replaced by an "import" residue which can have a smaller or larger side chain volume than the original residue. The import amino acid residue can be a naturally occurring or non-naturally occurring amino acid residue, but preferably is the former.

By "non-naturally occurring" amino acid residue is meant a residue which is not encoded by the genetic code, but which is able to covalently bind adjacent amino acid residue(s) in the polypeptide chain. Examples of non-naturally occurring amino acid residues are norleucine, ornithine, norvaline, homoserine and other amino acid residue analogues such as those described in Ellman et al., *Meth. Enzym.* 202:301-336 (1991), for example. To generate such non-naturally occurring amino acid residues, the procedures of Noren et al. *Science* 244: 182 (1989) and Ellman et al., supra can be used. Briefly, this involves chemically activating a suppressor tRNA with a non-naturally occurring amino acid residue followed by in vitro transcription and translation of the RNA. The methods of the current invention, in certain embodiments, involve replacing at least one original amino acid residue in an IgM heavy chain, but more than one original residue can be replaced. Normally, no more than the total residues in the interface of the first or second polypeptide will comprise original amino acid residues which are replaced. The preferred original residues for replacement are "buried". By "buried" is meant that the residue is essentially inaccessible to solvent. The preferred import residue is not cysteine to prevent possible oxidation or mispairing of disulfide bonds.

The protuberance is "positionable" in the cavity which means that the spatial location of the protuberance and cavity on the interface of the first polypeptide and second polypeptide respectively and the sizes of the protuberance and cavity are such that the protuberance can be located in the cavity without significantly perturbing the normal association of the first and second polypeptides at the interface. Since protuberances such as Tyr, Phe and Trp do not typically extend perpendicularly from the axis of the interface and have preferred conformations, the alignment of a protuberance with a corresponding cavity relies on modeling the protuberance/cavity pair based upon a three-dimensional structure such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR). This can be achieved using widely accepted techniques in the art, including techniques of molecular modeling.

By "original nucleic acid" is meant the nucleic acid encoding a polypeptide of interest which can be "altered" (i.e. genetically engineered or mutated) to encode a protuberance or cavity. The original or starting nucleic acid may be a naturally occurring nucleic acid or may comprise a nucleic acid which has been subjected to prior alteration (e.g. a humanized antibody fragment). By "altering" the nucleic acid is meant that the original nucleic acid is mutated by inserting, deleting or replacing at least one codon encoding an amino acid residue of interest. Normally, a codon

encoding an original residue is replaced by a codon encoding an import residue. Techniques for genetically modifying a DNA in this manner have been reviewed in *Mutagenesis: a Practical Approach*, M. J. McPherson, Ed., (IRL Press, Oxford, UK, (1991), and include site-directed mutagenesis, cassette mutagenesis and polymerase chain reaction (PCR) mutagenesis, for example.

The protuberance or cavity can be "introduced" into the interface of the first or second polypeptide by synthetic means, e.g. by recombinant techniques, in vitro peptide synthesis, those techniques for introducing non-naturally occurring amino acid residues previously described, by enzymatic or chemical coupling of peptides or some combination of these techniques. According, the protuberance or cavity which is "introduced" is "non-naturally occurring" or "non-native", which means that it does not exist in nature or in the original polypeptide (e.g. a humanized monoclonal antibody).

Preferably the import amino acid residue for forming the protuberance has a relatively small number of "rotamers" (e.g. about 3-6). A "rotamer" is an energetically favorable conformation of an amino acid side chain. The number of rotamers for the various amino acid residues are reviewed in Ponders and Richards, *J. Mol. Biol.* 193: 775-791 (1987).

The term "host cell" as used in the current application denotes any kind of cellular system which can be engineered to generate the antibodies according to the current invention. In one embodiment Chinese hamster ovary (CHO) cells are used as host cells.

As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.

A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, DNA for a pre-sequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

DETAILED DESCRIPTION

IgM is the first immunoglobulin produced by B cells in response to stimulation by antigen, and is present at around 1.5 mg/ml in serum with a half-life of 5 days. IgM is a pentameric or hexameric molecule. Just as IgG, IgM monomers consist of two light and two heavy chains. However, while IgG contains three heavy chain constant domains (CH1, CH2 and CH3), the heavy (μ) chain of IgM additionally contains a fourth constant domain (CH4), similarly to the c heavy chains in IgE. This extra constant domain is

located in place of the IgG and IgA proline-rich hinge region that is responsible for the rotational flexibility of the antigen-binding Fab domains relative to the Fc domain of IgG and IgA antibodies.

Five IgM monomers form a complex with an additional small polypeptide chain (the J chain) to form a native IgM molecule. The J chain is considered to facilitate polymerization of μ chains before IgM is secreted from antibody-producing cells. While crystallization of IgM has proved to be notoriously challenging, Czajkowsky and Shao (PNAS 106(35):14960-14965, 2009) recently published a homology-based structural model of IgM, based on the structure of the IgF Fc domain and the known disulfide pairings. The authors report that the human IgM pentamer is a mushroom-shaped molecule with a flexural bias.

In a natural penta- or hexameric IgM antibody molecule all heavy (μ) chains are identical and the light chains are identical as well. The present invention allows the production of IgM molecules in which two μ chains are different from each other.

In one aspect, the present invention concerns bispecific binding molecules with binding specificities to two different binding regions, having a penta- or hexameric structure, formed by five or six bispecific binding units, wherein each of such bispecific binding units has the same two binding specificities and comprises a first chain comprising at least a CM4 domain of an IgM heavy chain constant region conjugated to a first binding region to a first binding target, and a second chain comprising at least a CM4 domain of an IgM heavy chain constant region and a second binding region to a second binding target, wherein the first and second binding targets are different, and wherein the first and second chains are assembled to create a bispecific binding unit as a result of an asymmetric interface created between their respective IgM heavy chain constant regions.

In various embodiments, the IgM heavy chain constant regions additionally comprise one or both of the CM2 and CM3 domains or fragments thereof, and potentially other IgM heavy chain constant domain sequences. In one embodiment, the binding molecules of the present invention contain a complete IgM heavy (μ) chain constant domain, with one or more modifications to create an asymmetric interface between two heavy chains.

In order to generate an IgM molecule with two different μ heavy chains (chains A and B), a solution must be found for coupling the two matching μ heavy chains (A and B) with two different binding specificities to each other. In addition, if a light chain is needed to form a binding region, a solution must be found to couple each heavy chain with its matching light chain to provide the desired binding specificity.

The coupling can be achieved by salt bridge pairs charge switching (also referred to as charge swaps or charge reversals) between certain residues and/or by creating knobs-holes interactions between the two chains. The heavy chains can also be paired with their matching light chains by using the CrossMab technique. The different approaches can also be combined in order to achieve an optimal result.

In another aspect, the present invention concerns multi-specific binding molecules with binding specificities to two or more different binding targets, having a penta- or hexameric structure. The invention includes binding molecules comprising five or six monospecific binding units, where (i) each of the monospecific binding units comprises two IgM heavy chain constant regions each comprising at least a C μ 3 and C μ 4 domain conjugated to a binding region to a binding target, (ii) at least two of the monospecific binding units bind to different binding target. The invention further includes

binding molecules comprising five or six bispecific binding units, where (i) each of the bispecific binding units comprises two IgM heavy chain constant regions each comprising at least a C μ 3 and C μ 4 domain conjugated to a binding region to a binding target, and (ii) at least two of the bispecific binding units bind to different binding targets. In a particular embodiment, the binding molecules are multi-specific IgM antibodies.

In various embodiments, the IgM heavy chain constant regions additionally comprise a C μ 2 domain or a fragment thereof, and potentially other IgM heavy chain constant domain sequences. In one embodiment, the binding molecules of the present invention contain a complete IgM heavy (μ) chain constant domain, with one or more modifications to create an asymmetric interface between two heavy chains.

In the multi-specific binding molecules of the present invention which contain at least one bispecific binding unit, in order to generate an IgM molecule with two different μ heavy chains (chains A and B), a solution must be found for coupling the two matching μ heavy chains (A and B) with two different binding specificities to each other via an internal asymmetric interface. In addition, if a light chain is needed to form a binding region, a solution must be found to couple each heavy chain with its matching light chain to provide the desired binding specificity.

In addition, a solution must be found to create an external asymmetric interface between the heavy chain constant regions of the neighboring monospecific binding units that bind to different binding targets.

Techniques for creating internal and external asymmetric interfaces include, without limitation, salt bridge pairs charge switching (also referred to as charge swaps or charge reversals) between certain residues and creation of knobs-holes interactions between two chains. The heavy chains can also be paired with their matching light chains by using the CrossMab technique. The different approaches can also be combined in order to achieve an optimal result.

1. Knobs-into-Holes Technique

To improve the yields of the penta- or hexameric bispecific or multi-specific binding molecules of the present invention, the IgM heavy chain constant regions, e.g. the CM4, CM2 and/or CM3 domains, can be altered by the "knob-into-holes" technique which is described in detail with several examples in e.g. WO 96/027011, Ridgway, J., B., et al., Protein Eng 9 (1996) 617-621; and Merchant, A. M., et al., Nat Biotechnol 16 (1998) 677-681. In this method the interaction surfaces of two IgM heavy chain constant domains are altered to increase the heterodimerization of two heavy chains with different binding specificities and/or between a heavy chain and its matching light chain. Each of the two heavy chain domains, e.g. CM4-CM4, CM2-CM2 and/or CM2-CM3-CM4/CM2-CM3-CM4 can be the "knob", while the other is the "hole". The introduction of a disulfide bridge stabilizes the heterodimers (Merchant, A. M., et al., Nature Biotech 16 (1998) 677-681; Atwell, S., et al., J. Mol. Biol. 270 (1997) 26-35) and increases the yield. Similarly, the matching heavy and light chains can be coupled to each other by this technique Zhu, Z.; Presta, L. G.; Zapata, G.; Carter, P. *Remodeling domain interfaces to enhance heterodimer formation*. Prot. Sci. 6:781-788 (1997).

Following this approach, in the case of bispecific IgM binding molecules within the original interface of the C μ 14, CH2 and/or CH3 domains of one heavy chain that meets the original interface of the corresponding domain of the other heavy chain within the bispecific IgM binding molecule (e.g.

antibody), an amino acid residue may be replaced with an amino acid residue having a larger side chain volume, thereby creating a protuberance within the interface, which is positionable in a cavity within the interface of the corresponding domain in the other IgM heavy chain constant region. Similarly, the second IgM heavy chain may be altered, by replacing an amino acid residue within the interface with a corresponding domain in the constant region of the first IgM heavy chain, with an amino acid residue having a smaller side chain volume, thereby creating a hole (cavity) within the interface between the two heavy chain regions.

Human IgM CM4 and CM2 domain interface residues in knobs-holes positions are shown in Tables A and D. The Tables identify the native residue at the indicated positions of the IgM heavy chain constant region (SEQ ID NO: 33), with the CM4 sequence shown in FIG. 4D and the CM2 sequence shown in FIG. 4B, respectively, following the numbering shown in those Figures, as well as the potential mutations that can be used to create knobs-holes pairs. Thus, for example, in the CM4 domain the native threonine (T) residue in position 350 of SEQ ID NO: 33 may be mutated into tyrosine (Y) to create a knob, which can be combined with any combinations of the potential mutations listed for residues 352, 393 and 395 of SEQ ID NO: 33 of the native CM4 sequence (Set #1). Additional mutations at positions 254 and 397 of SEQ ID NO: 33, that can be optionally combined with Set #1 are shown in Set #2 and Set #3). Similarly, Set #4 exemplifies knobs mutations at positions 350 and 395 of SEQ ID NO: 33 in combination with hole mutations at one or more of positions 352, 393, 395, and 397 of SEQ ID NO: 33. Additional mutations for combination with Set#4 are listed in Set #5 and Set #6. The rest of Table A can be read in a similar way. Some of the sets also include charge introductions, i.e. changes from a non-charged residue to a charged residue (similarly to Table C discussed below).

It is emphasized that the listed knobs-holes mutations in Sets #1-30 can be used in various combinations as set forth in Table A. Furthermore, the listed mutations can be combined with other knobs-holes and/or charge swap and/or charge introduction mutations listed in the rest of the Tables. Thus, one or more of the knobs-holes mutations set forth in Table A can be combined with one or more of the knobs-holes mutations shown in Table D, in any combination and/or with one or more of the charge swap/charge introduction mutations listed in Tables B, C, E and F, as discussed hereinbelow. Thus, one can select any set from Table A and mix it with any set from Table B, mixed with any set from Table C, etc., in any order or combination.

2. Salt Bridge Pairs Charge Switching (Charge Swapping)

Opposite charges attract and similar charges repel each other. The charge of an amino acid molecule is pH dependent and can be characterized by the pK values, which are determined for the alpha amino group (N), the alpha carboxy group (C) and the side chain for free amino acids. The local environment can alter the pK_a of a side chain when the amino acid is part of a protein or peptide.

The charge properties of an amino acid molecule can also be characterized by the isoelectric point (pI), which is the pH at which the overall charge of the molecule is neutral. Since amino acids differ from each other in their side chains, the pI reflects differences in the pKs of the side chains.

Most amino acids (15/20) have a pI close to 6 so they are regarded as having neutral overall charge. Asp and Glu are negatively charged, and His, Lys, Arg are positively charged.

In the interface between two binding units in the mushroom-shaped IgM complex there are four salt bridges, above and below the disulfide bridge connecting the monomers. The residues involved in these interactions (Lys-238, Lys-268, Asp-293 and Asp294 of SEQ ID NO: 33) are the same in the two monomers, but their relative disposition in this interface is different, due to the asymmetry of the CM3 domains in the IgM Fc structure.

Positions and amino acid residues for charge swapping or charge introduction mutations are listed in Tables A, B, D, E, and F. As discussed above, or more of these mutations, or sets of mutations, can be combined with one or more sets of knobs-holes mutations to provide a desired asymmetric interface between two different IgM heavy chains and/or between an IgM heavy chain and its matching light chain.

Preferably, the asymmetric interface between two different IgM heavy chain constant regions is created by up to 8, such as, for example, 1-8, or 1-7, or 1-6, or 1-5, or 1-4, or 1-3, or 1-2 mutations in one IgM heavy chain, or 2-10, or 2-9, or 2-8, or 2-7, or 2-6, or 2-5, or 2-4, or 2-3 combined mutations in the two IgM heavy chains.

For multi-specific binding molecules herein, the external asymmetric interface is created by an alteration in the Cμ3 domain. In particular, to create an external asymmetric interface, a salt bridge is formed by pair-wise switches between oppositely charged amino acid residues in the Cμ3 domain. In various embodiments, the salt bridge providing the external asymmetric interface is formed by at least one pair-wise charged amino acid residue switch in the Cμ3-Cμ3 domains, which may, for example be K238↔D293 or K268↔D294 in the neighboring μ chains, where the amino acid coordinates refer to the human IgM heavy chain constant region of SEQ ID NO: 33.

3. CrossMab Technique

As discussed above, the knobs-into-holes technology or charge swapping enables heterodimerization of the antibody heavy chains. Correct association of the light chains and their cognate heavy chains can be achieved by exchange of heavy-chain and light-chain domains within the antigen binding fragment (Fab) of one half of the bispecific antibody. Crossover can occur as a crossover of the complete VH-CM and VL-CL domains, crossover of only the VH and VL domains, or the CM and CL domains within the one half of the bispecific binding unit of an IgM antibody. This "crossover" retains the antigen-binding affinity but makes the two arms so different that light-chain mispairing can no longer occur. For further details, in the context of IgG antibodies, see, for example, Schaeffer et al., (2011) *Proc Natl Acad Sci USA* 108(27): 11187-11192.

4. Production of Bispecific and Multi-Specific IgM Binding Molecules

The coding sequences of the heavy chains of the bispecific IgM antibody binding units, with the desired mutations (following the knobs-into-holes, charge swap and/or CrossMab technique) may be produced by introducing appropriate nucleotide changes into the antibody DNA, or by nucleotide synthesis. The antibodies can then be produced by recombinant means.

Methods for recombinant production are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody and usually purification to a pharmaceutically acceptable purity. For the expression of the antibodies in a host cell, nucleic acids encoding the respective modified heavy chains, and optionally light chains, are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells

like CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells, PER.C6 cells, yeast, or *E. coli* cells, and the antibody is recovered from the cells (supernatant or cells after lysis). General methods for recombinant production of antibodies are described, for example, in the review articles of Makrides, S. C., *Protein Expr. Purif* 17 (1999) 183-202; Geisse, S., et al., *Protein Expr. Purif* 8 (1996) 271-282; Kaufman, R. J. *Mol Biotechnol.* 16 (2000) 151-161; Wernier, R. S., *Drug Res.* 48 (1998) 870-880.

The bispecific and multi-specific antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-SEPHAROSE®, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Although due to its complex structure, the large scale production of recombinant IgM has been difficult, several recombinant production systems for IgM using non-lymphoid cells have been reported, including co-expression of the IgM heavy (H) and light (L) chains in C6 glioma cells, CHO cells, and Hef a cells. While the co-expression successfully resulted in the formation of polymer, the yields were typically low (see, e.g. WO89/01975 and Wood et al., *J. Immunol.* 145, 3011-3016 (1990) for expression in CHO cells), and the exact polymeric structure of the penta- or hexameric molecules could not be readily determined. Production of IgM in an immortalized human retina cell line expressing E1A and E1B proteins of an adenovirus is described in U. S. Application Publication No. 20060063234. Further details of the production of the bispecific IgM antibodies of the present invention are provided in the Example below.

The methods of the present invention will result in a composition comprising a bispecific or multi-specific IgM binding molecule, such as a bispecific or multi-specific IgM antibody, as the main component, in combination with various by-products of the manufacturing process, such as monospecific antibodies, antibody fragments, monomers, dimers, trimers, and/or tetramers of the bispecific binding unit, instead of the desired pentameric or hexameric structure. The compositions produced will generally contain at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 92%, or at least about 95%, of the desired penta- or hexameric bispecific binding molecule, e.g. antibody, which will be further purified by methods known in the art to yield a product with a purity of at least about 90%, or at least about 95%, or at least about 98%, or at least about 99%, or at least about 99.5%, or at least about 99.9%.

5. Applications of the Bispecific and Multi-Specific IgM Binding Molecules

The bispecific and multi-specific IgM binding molecules, e.g. antibodies, of the present invention have widespread therapeutic and diagnostic applications.

In one embodiment, the bispecific binding molecules herein bind to two sites on the same soluble target, such as, for example, VEGF, TNFα, or IL6. The purpose may, for example, be antagonizing multiple sites on the protein and/or increasing the avidity to a given target.

In another embodiment, the bispecific or multi-specific binding molecules herein bind two or more sites on the same cell surface (receptor) target, such as EGFR or HER2 (ErbB2). Thus, for example, a bispecific or multi-specific binding molecule might target both the 4D5 and the 2C4 epitopes on a HER2 molecule. This approach may increase bio-potency and/or avidity to a given target.

In yet another embodiment, the bispecific or multi-specific binding molecules of the present invention bind two or more different soluble targets (globular proteins or peptides), e.g. TNF α and IL-6, VEGF α and Ang2, or two cytokines. This approach might result in more complete blocking a specific pathway; blocking of the so called "cytokine storm," or coordinate an enzyme and its substrate, e.g. Factor IXa and Factor X.

In a further embodiment, the bispecific or multi-specific binding molecules herein may bind a soluble target and a cell surface receptor target, such as an angiogenic factor and neo-vascular specific receptor. The purpose of this approach may also be increased delivery and blockade at specific sites or tissues.

In a still further embodiment, the bispecific binding molecules herein are designed to bind two different cell surface receptor targets, such as, for example, HER2 (ErbB2) and HER3 (ErbB3). Similarly, the multi-specific binding molecules herein can be designed to bind two or more different cell surface receptor targets, such as, for example, HER1, HER2 (ErbB2) and HER3 (ErbB3). This may result in enhancing specificity and selectivity and/or in more complete blocking of a given pathway.

Bispecific and multi-specific binding molecules, such as antibodies, of the present invention may also be designed to bind one soluble target or cell surface receptor target and a long residence time target, such as, for example, TNF α and serum albumin, or VEGF and serum albumin. These molecules are expected to have longer circulating half-life than binding molecules without the albumin specificity.

In a further embodiment, the bispecific binding molecules herein may bind one soluble target and a matrix protein or a substrate, such as, for example, VEGF α and hyaluronic acid. Similarly, the multi-specific binding molecules herein may bind one or more soluble targets and one or more matrix proteins and/or substrates, such as, for example, VEGF α and hyaluronic acid. The resultant bi- or multi-specific binding molecules may find utility, for example, in anti-angiogenic therapy of ocular conditions, such as age-related macular degeneration (AMD), due to their increased residence time in the intraocular space.

Bispecific molecules, e.g. antibodies binding one soluble or receptor target, plus a transporter receptor (ie transferrin receptor), e.g. anti-EGFRvIII (mutant form with exon III deleted) found glioblastoma combined with anti-transferrin specificity, can find utility in antibody delivery across blood brain barrier.

Similarly, multi-specific molecules, e.g. antibodies binding one or more soluble or receptor targets, plus one or more transporter receptors (ie transferrin receptor), e.g. anti-EGFRvIII (mutant form with exon III deleted) found glioblastoma combined with anti-transferrin specificity, can find utility in antibody delivery across blood brain barrier.

6. Compositions, Pharmaceutical Compositions, and Methods of Treatment

In one aspect, the invention concerns compositions comprising purified bispecific or multi-specific IgM binding molecules, such as bispecific or multi-specific IgM antibodies herein. The compositions generally will contain at least about 80%, or at least about 85%, or at least about 90%, or at least about 92%, or at least about 95%, or at least about 98%, or at least about 99% of the desired bispecific or multi-specific IgM binding molecule, e.g. antibody. The composition may be a pharmaceutical composition, where the bispecific or multi-specific binding molecule, e.g. antibody, is in admixture with at least one pharmaceutically acceptable carrier.

A pharmaceutical composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the target disease or condition and the desired results. To administer a compound of the invention by certain routes of administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the compound may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art.

The compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and/or dispersing agents. Prevention of presence of microorganisms may be ensured both by sterilization procedures and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

The composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, the carrier preferably is an isotonic buffered saline solution.

The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention. Throughout the examples, where a mutation in an IgM heavy chain is referred to with the following formula: "X###Y," "X" refers to the native amino acid (single letter code), "###" refers to the coordinate in the wild-type human IgM constant region sequence presented herein as SEQ ID NO: 33, and "Y" refers to the mutated amino acid (single letter code).

All patent and scientific references cited throughout this disclosure are hereby expressly incorporated by reference herein.

25

Example 1

1. Generation of DNA Constructs with Designed Mutations

Materials and Methods

a. DNA Construct Synthesis

All DNA constructs with designed mutations were synthesized by commercial vendors (Genewiz, Inc.), with compatible restriction sites at both ends for subcloning into respective expression vectors, using methods well known in the art.

b. Construction of Expression Vectors

The synthesized DNA constructs were re-suspended in Tris-EDTA buffer at 1 µg/ml. DNA (1 µg) was subjected to enzyme digestion and the synthesized gene was separated from the carrier plasmid DNA by electrophoresis. The digested DNA was ligated to pre-digested plasmid DNA (pFUSEss-CHlg-hM*03 for µ chain; pFUSE2ss-CLlg-hk for kappa chain, InvivoGen) by standard molecular biology techniques. The ligated DNA was transformed into competent bacteria and plated on LB plates with multiple selective antibiotics. Several bacterial colonies were picked and DNA preparations were made by standard molecular biology techniques. The prepared DNA was verified by sequencing. Only the bacterial clones with 100% match of DNA sequence with the designed DNA sequence were used for plasmid DNA preparation and subsequently for cell transfection.

c. µ Chains of Different Size

In order to demonstrate that two different µ chains with or without CM4 interaction interface mutation (A and B) were able to couple together, two sets of different sized µ chains were constructed with distinct molecular weights and ligand specificities.

i. The Rtx chain is composed of a µ chain for the chimeric anti-CD20 antibody Rituxan (Rituximab) Vh region fused with the CM1 region of human IgM antibody µ chain with a C291S mutation and tail piece deletion:

(SEQ ID NO: 1)
 QVQLQPGAEVLKPGASVKMSCKASGYTFTSYNMHWKQTPGRGL
 EWIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSED
 SAVVYCARSTYYGGDWYFNWVGAGTTVTSSGSASAPTLFPLVSC
 ENSPDTSSVAVGCLAQDFLPDSITFSWKYKNSDISSTRGFPSV
 LRGGKYAATSQVLLPSKDVMTGTDHVVCKVQHPNGNKEKNVPLP
 VIAELPPKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWL
 REGKQVSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSM
 FTRVDRHGLTFQONASSMCVPDQDTAIRVFAIPPSFASIFLTKS
 TKLTCLVTDLTYYDSVTISWTRQNGEAVKTHNTNIESHPNATFSA
 VGEASISEDWNSGERFTCTVTHTDLPSPKQTISRPGKVALHRP
 DVYLLPPAREQLNLRESATITCLVTGFSADVFVQWMQRGQPLSP
 EKYVTSAPMPEPQAPGRYFAHSILTVSEEWNTGETYTCVVAHEA
 LPNRVTERTVD

The Rtx chain has a calculated molecular weight about 60 kD (without glycosylation) and 66 kD (with 4 N-glycosylation sites) and is able to bind to CD20 positive B cells, such as Raji cells.

26

ii. The Fc chain comprises human IgM µ chain CM2 to CM4 regions, carrying a cMyc tag and having its tail piece replaced by 6His tag (SEQ ID NO: 18) and having a C291S mutation:

(SEQ ID NO: 2)
 GSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREG
 KQVSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTC
 RVDHRGLTFQONASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKL
 TCLVTDLTYYDSVTISWTRQNGEAVKTHNTNIESHPNATFSAVGE
 ASISEDWNSGERFTCTVTHTDLPSPKQTISRPGKVALHRPDVY
 LLPPAREQLNLRESATITCLVTGFSADVFVQWMQRGQPLSPEKY
 VTSAPMPEPQAPGRYFAHSILTVSEEWNTGETYTCVVAHEALPN
 RVTERTVDKSTGKGGSEQKLISEEDLN SAVDHHHHHH

The Fc chain has a molecular weight about 39 kD (without glycosylation) and 43 kD (with 3 N-glycosylation sites) and is able to bind to anti-myc monoclonal antibody 9E4 or other anti-myc antibodies.

iii. The Okt chain is composed of a single chain Fv version of OKT3 (anti-CD3) fused with CM2 of human mu chain with C291S and tail piece deletion:

(SEQ ID NO: 3)
 QVQLQSGAEELARPGASVKMSCKASGYTFTRYTMHWKQRPQGGL
 WIGYINPSRGYTNYNQKFKDKATLTDDKSSSTAYMQLSSLTSEDSAVY
 YCARYDDHSLDYWGQGTTLTVSSGGGSGGGGSGGGGSIQVLTQS
 PAIMSASPGKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLAS
 GVP AHFRGSGSGTSYSLTISGMEAEADATYYCQWSSNPFTFGSGTKL
 EIKGSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREGK
 QVSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDH
 RGLTFQONASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCVTDLT
 YDSVTISWTRQNGEAVKTHNTNIESHPNATFSAVGEASISEDWNSGER
 FTCTVTHTDLPSPKQTISRPGKVALHRPDVYLLPPAREQLNLRESATIT
 CLVTGFSADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSIL
 TVSEEWNTGETYTCVVAHEALPNRVTERTVD

The Okt chain has a calculated molecular weight about 61 kD without glycosylation and 67 kD including 4 N-glycosylation sites, and is able to bind to CD3 positive T cells.

d. Light Chain Coupling

i. Native Chimeric Rituxan Kappa (κ) Chain

(SEQ ID NO: 4)
 QIVLSQSPAILSASPGKVTMTCRASSSVSYIHWFQKPGSPKPIYAT
 SNLASGVVPRFSGSGSGTSYSLTISRVEAEADATYYCQWSSNPPTFGG
 GTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVLNNFYRREAKVQWK
 VDNALQSGNSQESVTEQDSKDSYSLSTLTLSKADYKHKVYACEVT
 HQGLSSPVTKSFNRGEC

The kappa chain has a calculated molecular weight about 23 kD and is able to link to Rituxan IgM heavy chain.

e. Interface Mutations

Knobs and holes, electrostatic charge coupling were asymmetrically introduced into the CM3 interaction interface to maximize hetero-dimerization of two μ chains. Two pairs of CM3 interaction interface mutants were generated.

- i. Fc1a is a human μ chain CH2 to CH4 region with C291S and T350Y mutations and tail piece deletion:

(SEQ ID NO: 5)

```

GSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREGKQVG
SGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGL
TFQQNASSMCPVDQDTAIRVFAIPPSFASIFLIKSTKLTLCLVDTLTTYDS
VTISWTRQNGEAVKTHTNISESHPNATFSAVGEASISEDWNSGERFTC
TVTHTDLPSPKQTI SRPKGVALHRPDVYLLPPAREQLNLRESATIYCLV
TGFSADVFVQWQMRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS
EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK

```

The Fc1a chain has a calculated molecular weight about 36 kD without glycosylation and 41 kD if 3 N-glycosylation sites are included.

- ii. Fc1b is human μ chain CH2 to CH4 and with C291S, L352S and H395V mutations and tail piece deletion

(SEQ ID NO: 6)

```

GSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREGKQVG
SGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGL
TFQQNASSMCPVDQDTAIRVFAIPPSFASIFLIKSTKLTLCLVDTLTTYDS
VTISWTRQNGEAVKTHTNISESHPNATFSAVGEASISEDWNSGERFTC
TVTHTDLPSPKQTI SRPKGVALHRPDVYLLPPAREQLNLRESATIYCLV
TGFSADVFVQWQMRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS
EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK

```

The Fc1b chain has a calculated molecular weight about 36 kD without glycosylation and 41 kD including 3 N-glycosylation sites.

- iii. Fc2a consists of a human μ chain CH2 to CH4 region with C291S, T350Y, T354E, and I397E mutations and tail piece deletion.

(SEQ ID NO: 7)

```

GSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREGKQVG
SGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGL
TFQQNASSMCPVDQDTAIRVFAIPPSFASIFLIKSTKLTLCLVDTLTTYDS
VTISWTRQNGEAVKTHTNISESHPNATFSAVGEASISEDWNSGERFTC
TVTHTDLPSPKQTI SRPKGVALHRPDVYLLPPAREQLNLRESATIYCLV
TGFSADVFVQWQMRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS
EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK

```

The Fc2a chain has a calculated molecular weight of about 36 kD without glycosylation and 41 kD including 3 N-glycosylation sites.

- iv. Fc2b is human μ chain CH2 to CH4 and with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion.

(SEQ ID NO: 8)

```

GSGSKVSFVPPRDGFFGNPRKSKLICQATGFSRQIQVSWLREGKQVG
SGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGL
TFQQNASSMCPVDQDTAIRVFAIPPSFASIFLIKSTKLTLCLVDTLTTYDS
VTISWTRQNGEAVKTHTNISESHPNATFSAVGEASISEDWNSGERFTC
TVTHTDLPSPKQTI SRPKGVALHRPDVYLLPPAREQLNLRESATIYCLV
TGFSADVFVQWQMRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS
EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK

```

The Fc2b chain has a calculated molecular weight of about 36 kD without glycosylation and 41 kD including 3 N-glycosylation sites.

f. Interface Mutations

Fc2a chain and Fc2b chain with knobs, holes, and electrostatic charge coupling were further linked to both Rituxan and the OKT3 (anti-CD3 antibody) scFv by molecular cloning for asymmetrically hetero-dimerization of two μ chains.

- i. Rtx2a is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human μ chain with C291S, T350Y, T354E, and I397E mutations and tail piece deletion.

(SEQ ID NO: 9)

```

QVQLQQGAELVKGASVKMSCKASGYTFTSYNMHWKQTPGRGLE
WIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVY
YCARSTYYGGDWYFNWVGAGTTVTVSSGSASAPTLFPLVSCENSPSDT
SSVAVGCLAQDFLPDSITFSWKYKNSDISSTRGFPSVLRGKGYAATSQ
VLLPSKDVMMQGTDEHVCKVQHPNGNKEKNVPLFVIAELPPKVSFVFP
PRDGGFFGNPRKSKLICQATGFSRQIQVSWLREGKQVSGVTTDQVQAE
AKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRGLTFQQNASSMC
VPDQDTAIRVFAIPPSFASIFLIKSTKLTLCLVDTLTTYDSVTISWTRQNG
EAVKTHTNISESHPNATFSAVGEASISEDWNSGERFTCTVTHTDLPSP
KQTI SRPKGVALHRPDVYLLPPAREQLNLRESATIYCLV
TGFSADVFVQWQMRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS
EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK

```

The Rtx2a chain has a calculated molecular weight of about 61 kD without glycosylation and 67 kD with 4 N-glycosylation sites.

- ii. Rtx2b is composed of a μ chain for chimeric Rituxan (anti-CD20) Vh region fused with CM1 to CM4 of human μ chain with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion.

(SEQ ID NO: 10)

```

QVQLQQGAELVKGASVKMSCKASGYTFTSYNMHWKQTPGRGLE
WIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVY
YCARSTYYGGDWYFNWVGAGTTVTVSSGSASAPTLFPLVSCENSPSDT
SSVAVGCLAQDFLPDSITFSWKYKNSDISSTRGFPSVLRGKGYAATSQ
VLLPSKDVMMQGTDEHVCKVQHPNGNKEKNVPLFVIAELPPKVSFVFP

```


29

-continued

PRDGFNFRKSKLICATGESPRQIQVSWLREGKQVSGSVTTDQVQA
 EAKESGPTTYKVTSTLTIKESDNLQSMTFCRVDRGLTFQQNASSMC
 VPDQDTAIRVFAIPPSFASIFLTSTKLTCLVTLDTTYSVTISWTRQNG
 EAVKTHNTNISESHPNATFSAVGEASISEDWNSGERFTCTVHTDLPSP
 KQTISRPKGVALLHRPDVYLLPPAREQLNLRESATITCQVKGFSFADVFV
 QWMRGQPLSPEKYVTSAPMPEPQAPGRYFAVSCLTVSEEWNTGET
 YTCVVAHEALPNRVTERTVDKSTGK

The Rtx2b chain has a calculated molecular weight of about 61 kD without glycosylation and 67 kD including 4 N-glycosylation sites.

iii. Okt2a is composed of OKT3 (anti-CD3 antibody) scFv fused with CM2 to CM4 of human μ chain with C291S, T350Y, T354E, and I397E mutations and tail piece deletion.

(SEQ ID NO: 11)

QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKRPGQGLE
 WIGYINPSRGYTYNMQKFKDKATLTDDKSSSTAYMQLSSLTSEDSAVY
 YCARYDDHYSLDYWGQGTTLTVSSGGGSGGGSGGGSGQIVLTQS
 PAIMASPGKEKVTMTCSASSSVSYMNWYQKSGTSPKRWIYDTSKLAS
 GVPAAHFRGSGSGTYSYLTISGMEAEADAATYYCQWSSNPFTFGSGTKL
 EIKGSGSKVSFVPPRDPGFNPRKSKLICATGESPRQIQVSWLREGK
 QVSGSVTTDQVQAEAKESGPTTYKVTSTLTIKESDNLQSMTFCRVDRH
 RGLTFQQNASSMCPDQDTAIRVFAIPPSFASIFLTSTKLTCLVTLDTT
 YDSVTISWTRQNGEAVKTHNTNISESHPNATFSAVGEASISEDWNSGER
 FTCTVHTDLPSPKQTISRPKGVALLHRPDVYLLPPAREQLNLRESATIT
 CLVKGFSFADVFVQWMRGQPLSPEKYVTSAPMPEPQAPGRYFAVSCL
 LTVSEEWNTGETTYTCVVAHEALPNRVTERTVDKSTGK

The Okt2a chain has a calculated molecular weight about 62 kD without glycosylation and 68 kD including 4 N-glycosylation sites.

iv. Okt2b is composed of OKT3 (anti-CD3 antibody) scFv fused with CM2 to CM4 of human μ chain with C291S, L352S, T354K, H395V, and I397K mutations and tail piece deletion.

(SEQ ID NO: 12)

QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKRPGQGLE
 WIGYINPSRGYTYNMQKFKDKATLTDDKSSSTAYMQLSSLTSEDSAVY
 YCARYDDHYSLDYWGQGTTLTVSSGGGSGGGSGGGSGQIVLTQS
 PAIMASPGKEKVTMTCSASSSVSYMNWYQKSGTSPKRWIYDTSKLAS
 GVPAAHFRGSGSGTYSYLTISGMEAEADAATYYCQWSSNPFTFGSGTKL
 EIKGSGSKVSFVPPRDPGFNPRKSKLICATGESPRQIQVSWLREGK
 QVSGSVTTDQVQAEAKESGPTTYKVTSTLTIKESDNLQSMTFCRVDRH
 RGLTFQQNASSMCPDQDTAIRVFAIPPSFASIFLTSTKLTCLVTLDTT
 YDSVTISWTRQNGEAVKTHNTNISESHPNATFSAVGEASISEDWNSGER
 FTCTVHTDLPSPKQTISRPKGVALLHRPDVYLLPPAREQLNLRESATIT

30

-continued

CLVKGFSFADVFVQWMRGQPLSPEKYVTSAPMPEPQAPGRYFAVSCL
 TVSEEWNTGETTYTCVVAHEALPNRVTERTVDKSTGK

The Okt2b chain has a calculated molecular weight about 62 kD without glycosylation and 68 kD including 4 N-glycosylation sites.

2. Protein Expression, Purification and Characterization

a. Transfection

IgM was made by co-transfection of several different expression vectors at equal molar ratios into mammalian cells, such as 293F cells (Invitrogen). 10 μ g of mixed DNA for expression vectors were mixed with 20 μ l of 293fectin (Invitrogen) for 30 minutes at room temperature in 2 ml of Opti-MEM (Invitrogen) and then added to 10^7 293F cells. Transfections with 293F cells were incubated for 72 hours post-transfection before harvesting the supernatant.

b. Protein Purification by Immunoprecipitation.

i. Capture Select IgM (Catalog 2890.05, BAC, Thermo Fisher)

Transfected supernatant were harvested by centrifugation at 2,000 G for 10 minutes. IgM proteins were purified by immunoprecipitation with affinity Capture Select IgM affinity matrix. 100 μ l of Capture Select IgM slurry were added to 15 ml of harvested supernatant. The supernatant and affinity matrix mixtures were incubated at room temperature for 2 hours on a rocker. The affinity matrices were then centrifuged at 300 g for 2 minutes, decanting the solution. The affinity matrixes were further washed with PBS plus 0.05% Tween for 3 times. Finally, the purified IgM proteins were washed off from affinity matrices by incubating 20 μ l of 4xLSD sample loading buffer (Invitrogen) at room temperature for 5 minutes, followed by centrifuging at 10,000 g. The affinity matrixes were further washed with 60 μ l of PBS and the supernatant were pooled for analysis by gel electrophoresis.

c. Gel Electrophoresis

i. Non-Reducing SDS PAGE

Non-reducing SDS PAGE was used to separate various mutant IgM proteins of different molecular weights. Novex 4-12% Bis-Tris Gel (Life Technologies) was used with Novex MES SDS Running Buffer (Life Technologies).

ii. Reducing SDS-PAGE

NuPage LDS sample buffer (Life Technologies) and NuPage reducing agent dithiothreitol (Life Technologies) were added to IgM protein samples and heated to 80° C. for 10 minutes before loading on NuPage Novex 4-12% Bis-Tris Gel (Life Technologies, cat# NP0322). NuPage MES SDS Running Buffer (Life Technologies, cat# NP0002) was used for gel electrophoresis. After electrophoresis is complete, the gel was removed from the apparatus and stained using Colloidal Blue Staining (Life Technologies, manual #LC6025).

iii. Gel Band Quantitation

Protein gels are dried, then digitized using image scanner. The gel images are processed with Image J program and the amount of protein in a specific band is determined using the gel quantitation function.

iv. Analysis of SDS-PAGE Gels

Rtx:Fc including wild-type and engineered IgM Fc pair 2a and 2b SDS-PAGE gels. Lanes 1, 2, and 3 on the non-reduced SDS-PEG gel (FIG. 6) show an upper band for homodimeric Rtx (H2L2, expected MW 168-180 kDa) and a lower band for half-antibody (HL,

31

expected MW 84-90 kDa) for Rtx2a alone, Rtx2b alone and wild-type Rtx. A band for unassociated Fc (expected MW 36-41 kDa) is present in all three lanes; associated Fc (expected MW 72-82 kDa) may also be a component of the 80-90 kDa band. Lane 2 shows the mixture of Rtx2a:Fc2b and lane 3 shows the mixture of Rtx2b:Fc2a. In both lanes heterodimer (expected MW 120-131 kDa) is indicated with an arrow. The engineered Rtx2a:Fc2b and Rtx2b:Fc2a combinations both show the presence of significant heterodimer whereas the wild-type Rtx:Fc combination shows only a small amount of heterodimer.

The Fc is indeed present as seen in lanes 1-3 of the reduced SDS-PAGE shown in FIG. 7: top band is Rtx heavy chain (expected MW 61-67 kDa), middle band is Fc (expected MW 36-41 kDa), and bottom band is Rtx light chain (expected MW 23 kDa).

Okt:Fc including wild-type and engineered IgM Fc pair 2a and 2b, SDS-PAGE, FIG. 8, lanes 1-3

Wild-type Okt:Fc combination (SDS-PAGE, FIG. 8, lane 1) shows an upper band of Okt:Fc heterodimer (expected MW 98-107 kDa), a bottom band for unassociated Fc (expected MW 36-41) and a large middle band representing associated Fc (expected MW 72-82). In contrast, for the Okt2a:Fc2b and Okt2b:Fc2a combinations, the SDS-PAGE gel shown in FIG. 8, lane 2 shows a prominent band for the heterodimer and very light bands for associated Fc2b and the Okt2a homodimer above and congruent with the Okt2a:Fc2b heterodimer. The arrow indicates the heterodimer.

Both the Okt2a and Fc2b are present in the reduced gel (SDS-PAGE gel shown in FIG. 9, lane 2). Similar results are seen for the Okt2b:Fc2a pair on gels shown in FIGS. 8 and 9.

Okt:Rtx including wild-type and engineered IgM Fc pair 2a and 2b SDS-PAGE gels shown in FIGS. 8 and 9, lanes 4-6

Wild-type Okt:Rtx combination (SDS-PAGE gel shown in FIG. 8, lane 4) shows a band of wt Rtx homodimer (H2I.2, expected MW 168-180 kDa), a band of wt Rtx half-antibody (HL, expected MW 84-90 kDa) and a light band that may be Okt homodimer (expected MW 124-133 kDa). In contrast, the engineered Okt2a:Rtx2b combination (SDS-PAGE gel shown in FIG. 8, lane 5) shows the presence of significant heterodimer (expected MW 146-157) as well as Rtx2b homodimer (expected MW 168-180 kDa) and half-antibody (expected MW 84-90 kDa). When reduced (SDS-PAGE gel shown in FIG. 9, lane 5), the Rtx2b light chain shows a band at MW 23 kDa; the heavy band between 60-80 kDa is likely comprised of Rtx2b heavy chain (expected MW 61-67 kDa) and Okt2a heavy chain (expected MW 62-67 kDa). Similar results are seen for the Okt2b:Rtx2a pair.

Conclusions:

For all three systems tested—Okt:Rtx, Okt:Fc, Rtx:Fc—the engineered IgM Fc variants showed substantially increased heterodimer formation compared to native (non-engineered) IgM Fc. A single pair of sequences (i.e., Fcs 2a and 2b) were tested and additional variants of the engineered Fc interface can be evaluated to further reduce homodimer formation and optimize heterodimer formation.

3. Bispecific Functional Analysis

a. ELISA Analysis for Two Ligands

IgM with OKT3 (chain A) and cMyc peptide (chain B) is assayed by ELISA analysis with soluble CD3 epsilon protein capture and anti-cMyc (9E10) detection. Soluble CD3e

32

protein is coated on ELISA plate at 2 mg/ml in 150 mM of NaHCO₃ followed by blocking with 3% BSA in PBS. Supernatant (100 µl) containing transfected IgM-OKT3-cMyc is added to blocked ELISA plate for 4 hours at 25 C. After washing with PBS, the 9E10 antibody is added to the ELISA plate for 2 hours at room temperature. Anti-mouse IgG-HRP is added following washes with PBS. The existence of bi-specific IgM is detected by reading with OD 450 after adding HRP substrate.

IgM with Okt3 (chain A) and Rituxan (chain B) is assayed by ELISA analysis with soluble CD3 epsilon protein capture and Protein-L-HRP detection. Soluble CD3e protein is coated on ELISA plate at 2 mg/ml in 150 mM of NaHCO₃ following by blocking with 3% BSA in PBS. Supernatant (100 µl) containing transfected IgM-Okt3:Rtxb or Oktb:Rtxa is added to blocked ELISA plate for 4 hours at 25 C. After washing with PBS, the Protein-L-HRP is added to the ELISA plate for 2 hours at room temperature. The existence of bi-specific IgM is detected by reading with OD 450 after adding HRP substrate.

b. FACS Analysis of Target Binding

IgM-OKT3-cMyc binding to T cell is confirmed by binding of antibody to T cell line (Peer, positive cell line) and B cell line (Daudi, negative control cell line). After washing, rhodamine labeled 9E10 is added to the cell suspension. The cell target binding is detected by MFI of both positive and negative controlled cells with or without CD20 antigen.

c. Fluorescent Microscopy Assay for Bispecific Binding
Verify bispecific binding of the designed IgM by its ability to bring together, two populations of CD3 positive cells and CD20 positive cells, which have been pre-labeled by two different vital dyes on each cell type. For example:

- Green Fluorescent cytosolic vital dye (CellTrace™ Calcein Green AM) labeling for CD3 positive cell line (Peer)
- Red Fluorescent cytosolic vital dye (CellTrace™ Calcein Red-Orange, AM) labeled CD20 positive B-cell cell line (Daudi)

Example 2

1. Generation of DNA Constructs with Designed Mutations

DNA construct synthesis and construction of expression vectors are performed as in Example 1.

a. µ Chains of Different Size

The A chain is composed of a full length µ chain for chimeric OKT3 (anti-CD3) Vh region fused with CM1 of human mu chain:

(SEQ ID NO: 13)

QVQLQQSGAELARPGASVKMSCKASGYTFTTRYTMHWVKRPGGLEWIG

YINPSRGYTNYNQKFKDKATLTDDKSSSTAYMQLSSLTSEDVAVYYCAR

YYDDHYCLDYWGQGTTLTVSSGSASAPTLFPLVSCENSPSDTSSVAVGC

LAQDFLPDSITFSWKYKNNDSISSTRGFPSVLRRGGKYAATSQVLLPSKD

VMQGTDEHVVCVKVQHPNGNKEKNVPLPVAIELPFPKVSFVPPRDGFFGN

PRKSKLICQATGFSRQIQVSWLREGKQVSGVITDQVQAEAKESGPTT

YKVTSTLTIKESDWLSQSMFTCRVDHRLGTLFQQNASSMCPVDQDTAIRV

FAIPPSFASIFLTSTKTLCLVTLDTTYSVTISWTRQNGEAVKTHNTNI

SESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPKQTIISRPK

33

-continued

GVALHRPDVYLLPPAREQLNLRESATITCLVTGFSADVFVQWQMGQGP
LSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEWNTGETYTCVVAHEAL
PNRVTERTVDKSTGKPTLYNVSLVMSDAGTCY

The A chain has a molecular weight about 63 kD and is able to bind to soluble epsilon chain of CD3 (10977-H08H, Sino Biological), or T cells.

The B chain has a cMyc tag fused with CH2 of human μ chain:

(SEQ ID NO: 14)
QVQLGGPEQKLISEEDLNSAVLPVIAELPPKVSFVFPDGGFFGNPRKS
KLICQATGFSRQIQVSWLREGKQVSGSVTTDQVQAEAKESGPTTYKVT
STLTIKESDWLSQSMFTCRVDHRLTFQQNASSMCVPDQDTAIRVFAIP
PSFASIFLTKSTKLTLCLVTDLTYSVTISWTRQNGEAVKTHNTNISESH
PNATFSAVGEASICEDDWSNGERFTCTVTHDLPSPKQTIISRPGKVAL
HRPDVYLLPPAREQLNLRESATITCLVTGFSADVFVQWQMGQPLSPE
KYVTSAPMPEPQAPGRYFAHSILTVSEEWNTGETYTCVVAHEALPNRV
TERTVDKSTGKPTLYNVSLVMSDAGTCY

The B chain has a molecular weight about 41 kD and is able to bind to anti-myc monoclonal antibody 9E4 or other anti-myc antibodies.

The alternative B chain has a full length μ chain for CrossMab^{M-CL} (V_H+C_L) Rituximab (anti-CD20) fused with CH2 of human mu chain:

(SEQ ID NO: 15)
QVQLQQPGAEVLKPGASVKMSCKASGYTFTSYNMHWKQTPGRGLEWIG
AIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCAR
STYYGGDWYFNWVAGAGTTVTVSASVAAPSVFIPPPSDEQLKSGTASVVC
LLNNFYPREAKVQWVDNALQSGNSQESVTEQDSKSTYLSSTLTSLK
ADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHLPVIAELPPKVSFV
VPPRDGFFGNPRKSLIKQATGFSRQIQVSWLREGKQVSGSVTTDQVQ
AEAKESGPTTYKVTSTLTIKESDWLSQSMFTCRVDHRLTFQQNASSMC
VPDQDTAIRVFAIPPSFASIFLTKSTKLTLCLVTDLTYSVTISWTRQN
GEAVKTHNTNISESHPNATFSAVGEASICEDDWSNGERFTCTVTHDLP
PLKQTIISRPGKVALHRPDVYLLPPAREQLNLRESATITCLVTGFSADV
FVQWQMGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEWNTGET
YTCVVAHEALPNRVTERTVDESTGKPTLYNVSLVMSDAGTCY

The B chain has a molecular weight about 64 kD and is able to bind to CD20 positive B cells.

b. Different Light Chain Coupling
Native chimeric OKT3 kappa chain

(SEQ ID NO: 16)
QIVLTQSPAINASAPGKVTMTCSASSSVSYMNWYQQSGTSFKRWIYD
TSKLASGVPAHFRGSGSGTSYSLTISGMEAEADAATYYCQQWSSNPFTFG
SGTKLEINRAVAAPSVFIIPPSPDEQLKSGTASVVCLLNNFYPREAKVQW

34

-continued

KVDNALQSGNSQESVTEQDSKSTYLSSTLTSLSKADYEKHKVYACEVT
HQGLSSPVTKSFNRGEC

CrossMab^{CM1-CL} for Rituximab

(SEQ ID NO: 17)
10 QIVLSQSPAILASAPGKVTMTCRASSSVSYIHWFPQQKPGSSPKWIIYA
TSNLASGVPAHFRGSGSGTSYSLTISRVEAEADAATYYCQQWTSNPFTFG
GGTKLEIKSSASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
15 SWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHK
PSNTKVDKREVEPKSC

c. Different Selection Markers for Different Expression Vectors

20 Different selection markers are used on different expression vectors used for co-transfection. Multiple drugs are used for selection of cells in order to accommodate all necessary expression vectors relevant for IgM production. Standard molecular biology techniques are used for cloning specific DNAs into these vectors.

25 i. Mu chain utilizes Zeocin selection (ant-zn-1, Invivo-gen). Zeocin is used at a concentration of 100 μ g/ml. After transfection with a plasmid containing the Sh ble gene, then the cells are incubated in Opti-CHO medium containing Zeocin at 100 μ g/ml to select for stable transfectants.
ii. Kappa chain utilizes Blasticidin S selection (ant-bl-1, Invivogen). Blasticidin S is used at a concentration of 10 μ g/ml. After transfection with a plasmid containing the bsr gene, then the cells are incubated in Opti-CHO medium containing Blasticidin S at 10 μ g/ml to select for stable transfectants.

d. Protein Expression, Purification and Characterization
i. Transfection

40 IgM is made by co-transfection of several different expression vectors at equal molar ratios or variable molar ratio (5 to 10 fold difference) into mammalian cells, such as 293 cells or CHO cells. DNA for expression vectors are mixed with PEI and then added to CHO-S cells. PEI transfection with CHO-S cells is conducted according to established techniques (see "Biotechnology and Bioengineering, Vol 87, 553-545").

ii. Protein Purification

50 Capture Select IgM (Catalog 2890.05, BAC, Thermo Fisher)

IgM proteins from transfected CHO-S cell supernatants are purified by affinity Capture Select IgM affinity matrix according to manufacturers' protocol.

55 Capto-L (Catalog 17-5478-01, GE Healthcare)

Transfected IgM protein, containing kappa chain, in CHO-S cell supernatant is purified by Capto-L affinity matrix according to manufacturers' protocol

iii. Gel Electrophoresis

60 Non-Reducing SDS PAGE

Non-reducing SDS PAGE separates native IgM and its mutant forms according to size. Pentameric IgM, composed of homodimeric heavy chains (AA), produces a protein band of approximately 1,000,000 molecular weight. Pentameric IgM composed of a shorter version of homodimeric heavy chains (BB) produces a protein band of significantly lower molecular weight. Pentam-

35

eric IgM composed of heterodimeric heavy chains (chimeric AB) produce multiple proteins with molecular weights greater than BB and less than AA.

NuPage LDS Sample Buffer (Life Technologies) is added to IgM protein samples at 25 C for 30 minutes before loading onto the gel. NativePage Novex 3-12% Bis-Tris Gel (Life Technologies) is used with Novex Tris-Acetate SDS Running Buffer (Life Technologies). Run gel until the dye front reaches the bottom of the gel.

Reducing SDS-PAGE

NuPage LDS sample buffer (Life Technologies) and NuPage reducing agent dithiothreitol (Life Technologies) are added to IgM protein samples and heated to 80° C. for 10 minutes before loading on NuPage Novex 4-12% Bis-Tris Gel (Life Technologies, cat# NP0322). NuPage MES SDS Running Buffer (Life Technologies, cat# NP0002) is used for gel electrophoresis. Gels are run until the dye front reaches the bottom of the gel.

After electrophoresis is complete, remove gel from apparatus and stain the gel using Colloidal Blue Staining (Life Technologies, manual #LC6025)

Gel Band Quantitation

Protein gels are dried, then digitized using image scanner. The gel image is processed with Image J program and the amount of protein in a specific band can be determined using the gel quantitation function

iv. Mass Spectrometric Analysis to Identify/Quantify the Various mAbs in the Bi-Specific Preparation.

v. Stability Analysis Using Differential Scanning Calorimetry (DSC)

e. Bi-Specific Functional Analysis

i. ELISA Analysis for Two Ligands

IgM with OKT3 (chain A) and cMyc peptide (chain B) is assayed by ELISA analysis with soluble CD3 epsilon

36

protein capture and anti-cMyc (9E10) detection. Soluble CD3e protein is coated on ELISA plate at 2 mg/ml in 150 mM of NaHCO₃ followed by blocking with 3% BSA in PBS. Supernatant (100 µl) containing transfected IgM-OKT3-cMyc is added to blocked ELISA plate for 4 hours at 25 C. After washing with PBS, the 9E10 antibody is added to the ELISA plate for 2 hours at room temperature. Anti-mouse IgG-HRP is added following washes with PBS. The existence of bi-specific IgM is detected by reading with OD 450 after adding HRP substrate.

ii. FACS Analysis of Target Binding

IgM-OKT3-cMyc binding to T cell is confirmed by binding of antibody to T cell line (Peer, positive cell line) and B cell line (Daudi, negative control cell line). After washing, rhodamine labeled 9E10 is added to the cell suspension. The cell target binding is detected by MFI of both positive and negative controlled cells with or without CD20 antigen.

iii. Fluorescent Microscopy Assay for Bi-Specific Binding

Verify bi-specific binding of the designed IgM by its ability to bring together, two populations of CD3 positive cells and CD20 positive cells, which have been pre-labeled by two different vital dyes on each cell type. For example:

Green Fluorescent cytosolic vital dye (CellTrace™ Calcein Green AM) labeling for CD3 positive cell line (Peer)

Red Fluorescent cytosolic vital dye (CellTrace™ Calcein Red-Orange, AM) labeled CD20 positive B-cell line (Daudi)

Multi-specific binding and multi-specific functional analysis can be performed in a similar manner using techniques known in the art, such as those described above.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 33

<210> SEQ ID NO 1

<211> LENGTH: 551

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 1

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
100 105 110

Ala Gly Thr Thr Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro Thr
115 120 125

-continued

Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser Ser
 130 135 140
 Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile Thr
 145 150 155 160
 Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg Gly
 165 170 175
 Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln Val
 180 185 190
 Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu His Val Val
 195 200 205
 Cys Lys Val Gln His Pro Asn Gly Asn Lys Glu Lys Asn Val Pro Leu
 210 215 220
 Pro Val Ile Ala Glu Leu Pro Pro Lys Val Ser Val Phe Val Pro Pro
 225 230 235 240
 Arg Asp Gly Phe Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln
 245 250 255
 Ala Thr Gly Phe Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu
 260 265 270
 Gly Lys Gln Val Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu
 275 280 285
 Ala Lys Glu Ser Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr
 290 295 300
 Ile Lys Glu Ser Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val
 305 310 315 320
 Asp His Arg Gly Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val
 325 330 335
 Pro Asp Gln Asp Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe
 340 345 350
 Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr
 355 360 365
 Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn
 370 375 380
 Gly Glu Ala Val Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn
 385 390 395 400
 Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp
 405 410 415
 Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro
 420 425 430
 Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His
 435 440 445
 Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu
 450 455 460
 Arg Glu Ser Ala Thr Ile Thr Cys Leu Val Thr Gly Phe Ser Pro Ala
 465 470 475 480
 Asp Val Phe Val Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu
 485 490 495
 Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg
 500 505 510
 Tyr Phe Ala His Ser Ile Leu Thr Val Ser Glu Glu Glu Trp Asn Thr
 515 520 525
 Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg
 530 535 540

-continued

Val Thr Glu Arg Thr Val Asp
545 550

<210> SEQ ID NO 2
<211> LENGTH: 353
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 2

Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
1 5 10 15
Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
20 25 30
Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
35 40 45
Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
50 55 60
Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
65 70 75 80
Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
85 90 95
Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
100 105 110
Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
115 120 125
Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
130 135 140
Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
145 150 155 160
Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
165 170 175
Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
180 185 190
Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
195 200 205
Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
210 215 220
Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
225 230 235 240
Thr Ile Thr Cys Leu Val Thr Gly Phe Ser Pro Ala Asp Val Phe Val
245 250 255
Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
260 265 270
Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His
275 280 285
Ser Ile Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr
290 295 300
Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
305 310 315 320
Thr Val Asp Lys Ser Thr Gly Lys Gly Gly Gly Ser Glu Gln Lys Leu
325 330 335
Ile Ser Glu Glu Asp Leu Asn Ser Ala Val Asp His His His His His
340 345 350

-continued

His

<210> SEQ ID NO 3
 <211> LENGTH: 563
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 3

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30
 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Tyr Tyr Asp Asp His Tyr Ser Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly
 115 120 125
 Ser Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
 130 135 140
 Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
 145 150 155 160
 Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
 165 170 175
 Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
 180 185 190
 Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
 195 200 205
 Ser Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
 210 215 220
 Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 225 230 235 240
 Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
 245 250 255
 Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
 260 265 270
 Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
 275 280 285
 Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
 290 295 300
 Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
 305 310 315 320
 Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
 325 330 335
 Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
 340 345 350

-continued

Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
 355 360 365
 Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
 370 375 380
 Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
 385 390 395 400
 Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
 405 410 415
 Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
 420 425 430
 Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
 435 440 445
 Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
 450 455 460
 Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
 465 470 475 480
 Thr Ile Thr Cys Leu Val Thr Gly Phe Ser Pro Ala Asp Val Phe Val
 485 490 495
 Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
 500 505 510
 Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His
 515 520 525
 Ser Ile Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr
 530 535 540
 Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
 545 550 555 560
 Thr Val Asp

<210> SEQ ID NO 4
 <211> LENGTH: 213
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 4

Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
 20 25 30
 His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
 35 40 45
 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
 65 70 75 80
 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
 100 105 110
 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
 115 120 125
 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
 130 135 140

-continued

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
 145 150 155 160
 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 165 170 175
 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
 180 185 190
 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 195 200 205
 Asn Arg Gly Glu Cys
 210

<210> SEQ ID NO 5
 <211> LENGTH: 328
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 5

Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
 1 5 10 15
 Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
 20 25 30
 Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
 35 40 45
 Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
 50 55 60
 Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
 65 70 75 80
 Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
 85 90 95
 Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
 100 105 110
 Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
 115 120 125
 Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
 130 135 140
 Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
 145 150 155 160
 Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
 165 170 175
 Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
 180 185 190
 Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
 195 200 205
 Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
 210 215 220
 Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
 225 230 235 240
 Thr Ile Tyr Cys Leu Val Thr Gly Phe Ser Pro Ala Asp Val Phe Val
 245 250 255
 Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
 260 265 270
 Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His

-continued

275	280	285
Ser Ile Leu Thr Val	Ser Glu Glu Trp	Asn Thr Gly Glu Thr Tyr
290	295	300
Thr Cys Val Val Ala His Glu Ala Leu Pro	Asn Arg Val Thr Glu Arg	
305	310	315 320
Thr Val Asp Lys Ser Thr Gly Lys		
325		

<210> SEQ ID NO 6
 <211> LENGTH: 328
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 6

Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe	
1 5 10 15	
Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe	
20 25 30	
Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val	
35 40 45	
Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser	
50 55 60	
Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser	
65 70 75 80	
Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly	
85 90 95	
Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp	
100 105 110	
Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe	
115 120 125	
Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr	
130 135 140	
Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val	
145 150 155 160	
Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser	
165 170 175	
Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu	
180 185 190	
Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys	
195 200 205	
Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val	
210 215 220	
Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala	
225 230 235 240	
Thr Ile Thr Cys Ser Val Thr Gly Phe Ser Pro Ala Asp Val Phe Val	
245 250 255	
Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr	
260 265 270	
Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala Val	
275 280 285	
Ser Ile Leu Thr Val Ser Glu Glu Trp Asn Thr Gly Glu Thr Tyr	
290 295 300	

-continued

Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
305 310 315 320

Thr Val Asp Lys Ser Thr Gly Lys
325

<210> SEQ ID NO 7

<211> LENGTH: 328

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 7

Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
1 5 10 15

Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
20 25 30

Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
35 40 45

Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
50 55 60

Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
65 70 75 80

Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
85 90 95

Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
100 105 110

Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
115 120 125

Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
130 135 140

Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
145 150 155 160

Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
165 170 175

Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
180 185 190

Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
195 200 205

Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
210 215 220

Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
225 230 235 240

Thr Ile Tyr Cys Leu Val Glu Gly Phe Ser Pro Ala Asp Val Phe Val
245 250 255

Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
260 265 270

Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His
275 280 285

Ser Glu Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr
290 295 300

Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
305 310 315 320

Thr Val Asp Lys Ser Thr Gly Lys
325

-continued

<210> SEQ ID NO 8
 <211> LENGTH: 328
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 8

Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
 1 5 10 15
 Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
 20 25 30
 Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
 35 40 45
 Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
 50 55 60
 Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
 65 70 75 80
 Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
 85 90 95
 Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
 100 105 110
 Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
 115 120 125
 Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
 130 135 140
 Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
 145 150 155 160
 Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
 165 170 175
 Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
 180 185 190
 Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
 195 200 205
 Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
 210 215 220
 Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
 225 230 235 240
 Thr Ile Thr Cys Ser Val Lys Gly Phe Ser Pro Ala Asp Val Phe Val
 245 250 255
 Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
 260 265 270
 Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala Val
 275 280 285
 Ser Lys Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr
 290 295 300
 Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
 305 310 315 320
 Thr Val Asp Lys Ser Thr Gly Lys
 325

<210> SEQ ID NO 9
 <211> LENGTH: 556
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 9

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45
 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
 100 105 110
 Ala Gly Thr Thr Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro Thr
 115 120 125
 Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser Ser
 130 135 140
 Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile Thr
 145 150 155 160
 Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg Gly
 165 170 175
 Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln Val
 180 185 190
 Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu His Val Val
 195 200 205
 Cys Lys Val Gln His Pro Asn Gly Asn Lys Glu Lys Asn Val Pro Leu
 210 215 220
 Pro Val Ile Ala Glu Leu Pro Pro Lys Val Ser Val Phe Val Pro Pro
 225 230 235 240
 Arg Asp Gly Phe Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln
 245 250 255
 Ala Thr Gly Phe Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu
 260 265 270
 Gly Lys Gln Val Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu
 275 280 285
 Ala Lys Glu Ser Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr
 290 295 300
 Ile Lys Glu Ser Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val
 305 310 315 320
 Asp His Arg Gly Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val
 325 330 335
 Pro Asp Gln Asp Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe
 340 345 350
 Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr
 355 360 365
 Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn
 370 375 380

-continued

Gly Glu Ala Val Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn
 385 390 395 400
 Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp
 405 410 415
 Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro
 420 425 430
 Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His
 435 440 445
 Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu
 450 455 460
 Arg Glu Ser Ala Thr Ile Tyr Cys Leu Val Glu Gly Phe Ser Pro Ala
 465 470 475 480
 Asp Val Phe Val Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu
 485 490 495
 Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg
 500 505 510
 Tyr Phe Ala His Ser Glu Leu Thr Val Ser Glu Glu Glu Trp Asn Thr
 515 520 525
 Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg
 530 535 540
 Val Thr Glu Arg Thr Val Asp Lys Ser Thr Gly Lys
 545 550 555

<210> SEQ ID NO 10
 <211> LENGTH: 556
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 10

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45
 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
 100 105 110
 Ala Gly Thr Thr Val Thr Val Ser Ser Gly Ser Ala Ser Ala Pro Thr
 115 120 125
 Leu Phe Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser Ser
 130 135 140
 Val Ala Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile Thr
 145 150 155 160
 Phe Ser Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg Gly
 165 170 175
 Phe Pro Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln Val
 180 185 190

-continued

```

Leu Leu Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu His Val Val
 195                      200                      205

Cys Lys Val Gln His Pro Asn Gly Asn Lys Glu Lys Asn Val Pro Leu
 210                      215                      220

Pro Val Ile Ala Glu Leu Pro Pro Lys Val Ser Val Phe Val Pro Pro
 225                      230                      235                      240

Arg Asp Gly Phe Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln
 245                      250                      255

Ala Thr Gly Phe Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu
 260                      265                      270

Gly Lys Gln Val Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu
 275                      280                      285

Ala Lys Glu Ser Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr
 290                      295                      300

Ile Lys Glu Ser Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val
 305                      310                      315                      320

Asp His Arg Gly Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val
 325                      330                      335

Pro Asp Gln Asp Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe
 340                      345                      350

Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr
 355                      360                      365

Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn
 370                      375                      380

Gly Glu Ala Val Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn
 385                      390                      395                      400

Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp
 405                      410                      415

Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro
 420                      425                      430

Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His
 435                      440                      445

Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu
 450                      455                      460

Arg Glu Ser Ala Thr Ile Thr Cys Ser Val Lys Gly Phe Ser Pro Ala
 465                      470                      475                      480

Asp Val Phe Val Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu
 485                      490                      495

Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg
 500                      505                      510

Tyr Phe Ala Val Ser Lys Leu Thr Val Ser Glu Glu Glu Trp Asn Thr
 515                      520                      525

Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg
 530                      535                      540

Val Thr Glu Arg Thr Val Asp Lys Ser Thr Gly Lys
 545                      550                      555

```

<210> SEQ ID NO 11

<211> LENGTH: 568

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

-continued

<400> SEQUENCE: 11

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30
 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Tyr Tyr Asp Asp His Tyr Ser Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 115 120 125
 Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
 130 135 140
 Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
 145 150 155 160
 Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
 165 170 175
 Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
 180 185 190
 Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
 195 200 205
 Ser Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
 210 215 220
 Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 225 230 235 240
 Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe
 245 250 255
 Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe
 260 265 270
 Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val
 275 280 285
 Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser
 290 295 300
 Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser
 305 310 315 320
 Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly
 325 330 335
 Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp
 340 345 350
 Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe
 355 360 365
 Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr
 370 375 380
 Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val
 385 390 395 400
 Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser
 405 410 415

-continued

Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu
420 425 430

Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys
435 440 445

Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val
450 455 460

Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala
465 470 475 480

Thr Ile Tyr Cys Leu Val Glu Gly Phe Ser Pro Ala Asp Val Phe Val
485 490 495

Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr
500 505 510

Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His
515 520 525

Ser Glu Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr
530 535 540

Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg
545 550 555 560

Thr Val Asp Lys Ser Thr Gly Lys
565

<210> SEQ ID NO 12
<211> LENGTH: 568
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 12

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Ser Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
130 135 140

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
145 150 155 160

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
165 170 175

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
180 185 190

Ala His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile

-continued

195	200	205
Ser Gly Met Glu Ala Glu Asp	Ala Ala Thr Tyr Tyr Cys Gln Gln Trp	
210	215	220
Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys		
225	230	235
Gly Ser Gly Ser Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe		
245	250	255
Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe		
260	265	270
Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val		
275	280	285
Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser		
290	295	300
Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser		
305	310	315
Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly		
325	330	335
Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp		
340	345	350
Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe		
355	360	365
Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr		
370	375	380
Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val		
385	390	395
Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser		
405	410	415
Ala Val Gly Glu Ala Ser Ile Ser Glu Asp Asp Trp Asn Ser Gly Glu		
420	425	430
Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys		
435	440	445
Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val		
450	455	460
Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala		
465	470	475
Thr Ile Thr Cys Ser Val Lys Gly Phe Ser Pro Ala Asp Val Phe Val		
485	490	495
Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr		
500	505	510
Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala Val		
515	520	525
Ser Lys Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr		
530	535	540
Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg		
545	550	555
Thr Val Asp Lys Ser Thr Gly Lys		
565		

<210> SEQ ID NO 13

<211> LENGTH: 572

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

-continued

<400> SEQUENCE: 13

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30
 Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
 100 105 110
 Thr Thr Leu Thr Val Ser Ser Gly Ser Ala Ser Ala Pro Thr Leu Phe
 115 120 125
 Pro Leu Val Ser Cys Glu Asn Ser Pro Ser Asp Thr Ser Ser Val Ala
 130 135 140
 Val Gly Cys Leu Ala Gln Asp Phe Leu Pro Asp Ser Ile Thr Phe Ser
 145 150 155 160
 Trp Lys Tyr Lys Asn Asn Ser Asp Ile Ser Ser Thr Arg Gly Phe Pro
 165 170 175
 Ser Val Leu Arg Gly Gly Lys Tyr Ala Ala Thr Ser Gln Val Leu Leu
 180 185 190
 Pro Ser Lys Asp Val Met Gln Gly Thr Asp Glu His Val Val Cys Lys
 195 200 205
 Val Gln His Pro Asn Gly Asn Lys Glu Lys Asn Val Pro Leu Pro Val
 210 215 220
 Ile Ala Glu Leu Pro Pro Lys Val Ser Val Phe Val Pro Pro Arg Asp
 225 230 235 240
 Gly Phe Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr
 245 250 255
 Gly Phe Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly Lys
 260 265 270
 Gln Val Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala Lys
 275 280 285
 Glu Ser Gly Pro Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys
 290 295 300
 Glu Ser Asp Trp Leu Ser Gln Ser Met Phe Thr Cys Arg Val Asp His
 305 310 315 320
 Arg Gly Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys Val Pro Asp
 325 330 335
 Gln Asp Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe Ala Ser
 340 345 350
 Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr Asp Leu
 355 360 365
 Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu
 370 375 380
 Ala Val Lys Thr His Thr Asn Ile Ser Glu Ser His Pro Asn Ala Thr
 385 390 395 400
 Phe Ser Ala Val Gly Glu Ala Ser Ile Cys Glu Asp Asp Trp Asn Ser

-continued

405	410	415
Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro Ser Pro		
420	425	430
Leu Lys Gln Thr Ile Ser Arg Pro Lys Gly Val Ala Leu His Arg Pro		
435	440	445
Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu		
450	455	460
Ser Ala Thr Ile Thr Cys Leu Val Thr Gly Phe Ser Pro Ala Asp Val		
465	470	475
Phe Val Gln Trp Met Gln Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr		
485	490	495
Val Thr Ser Ala Pro Met Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe		
500	505	510
Ala His Ser Ile Leu Thr Val Ser Glu Glu Glu Trp Asn Thr Gly Glu		
515	520	525
Thr Tyr Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg Val Thr		
530	535	540
Glu Arg Thr Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val		
545	550	555
Ser Leu Val Met Ser Asp Thr Ala Gly Thr Cys Tyr		
565	570	

<210> SEQ ID NO 14

<211> LENGTH: 372

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 14

Gln Val Gln Leu Gly Gly Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp		
1	5	10
Leu Asn Ser Ala Val Leu Pro Val Ile Ala Glu Leu Pro Pro Lys Val		
20	25	30
Ser Val Phe Val Pro Pro Arg Asp Gly Phe Phe Gly Asn Pro Arg Lys		
35	40	45
Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe Ser Pro Arg Gln Ile Gln		
50	55	60
Val Ser Trp Leu Arg Glu Gly Lys Gln Val Gly Ser Gly Val Thr Thr		
65	70	75
Asp Gln Val Gln Ala Glu Ala Lys Glu Ser Gly Pro Thr Thr Tyr Lys		
85	90	95
Val Thr Ser Thr Leu Thr Ile Lys Glu Ser Asp Trp Leu Ser Gln Ser		
100	105	110
Met Phe Thr Cys Arg Val Asp His Arg Gly Leu Thr Phe Gln Gln Asn		
115	120	125
Ala Ser Ser Met Cys Val Pro Asp Gln Asp Thr Ala Ile Arg Val Phe		
130	135	140
Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys		
145	150	155
Leu Thr Cys Leu Val Thr Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile		
165	170	175
Ser Trp Thr Arg Gln Asn Gly Glu Ala Val Lys Thr His Thr Asn Ile		
180	185	190

-continued

Ser Glu Ser His Pro Asn Ala Thr Phe Ser Ala Val Gly Glu Ala Ser
 195 200 205
 Ile Cys Glu Asp Asp Trp Asn Ser Gly Glu Arg Phe Thr Cys Thr Val
 210 215 220
 Thr His Thr Asp Leu Pro Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro
 225 230 235 240
 Lys Gly Val Ala Leu His Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala
 245 250 255
 Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala Thr Ile Thr Cys Leu Val
 260 265 270
 Thr Gly Phe Ser Pro Ala Asp Val Phe Val Gln Trp Met Gln Arg Gly
 275 280 285
 Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr Ser Ala Pro Met Pro Glu
 290 295 300
 Pro Gln Ala Pro Gly Arg Tyr Phe Ala His Ser Ile Leu Thr Val Ser
 305 310 315 320
 Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr Thr Cys Val Val Ala His
 325 330 335
 Glu Ala Leu Pro Asn Arg Val Thr Glu Arg Thr Val Asp Lys Ser Thr
 340 345 350
 Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val Met Ser Asp Thr Ala
 355 360 365
 Gly Thr Cys Tyr
 370

<210> SEQ ID NO 15
 <211> LENGTH: 582
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 15

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45
 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly
 100 105 110
 Ala Gly Thr Thr Val Thr Val Ser Ala Ser Val Ala Ala Pro Ser Val
 115 120 125
 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
 130 135 140
 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
 145 150 155 160
 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val
 165 170 175

-continued

Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu
 180 185 190
 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu
 195 200 205
 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg
 210 215 220
 Gly Glu Cys Asp Lys Thr His Leu Pro Val Ile Ala Glu Leu Pro Pro
 225 230 235 240
 Lys Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe Phe Gly Asn Pro
 245 250 255
 Arg Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe Ser Pro Arg Gln
 260 265 270
 Ile Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val Gly Ser Gly Val
 275 280 285
 Thr Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser Gly Pro Thr Thr
 290 295 300
 Tyr Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser Asp Trp Leu Ser
 305 310 315 320
 Gln Ser Met Phe Thr Cys Arg Val Asp His Arg Gly Leu Thr Phe Gln
 325 330 335
 Gln Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp Thr Ala Ile Arg
 340 345 350
 Val Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe Leu Thr Lys Ser
 355 360 365
 Thr Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr Tyr Asp Ser Val
 370 375 380
 Thr Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val Lys Thr His Thr
 385 390 395 400
 Aon Ile Ser Glu Ser His Pro Aon Ala Thr Phe Ser Ala Val Gly Glu
 405 410 415
 Ala Ser Ile Cys Glu Asp Asp Trp Asn Ser Gly Glu Arg Phe Thr Cys
 420 425 430
 Thr Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys Gln Thr Ile Ser
 435 440 445
 Arg Pro Lys Gly Val Ala Leu His Arg Pro Asp Val Tyr Leu Leu Pro
 450 455 460
 Pro Ala Arg Glu Gln Leu Asn Leu Arg Glu Ser Ala Thr Ile Thr Cys
 465 470 475 480
 Leu Val Thr Gly Phe Ser Pro Ala Asp Val Phe Val Gln Trp Met Gln
 485 490 495
 Arg Gly Gln Pro Leu Ser Pro Glu Lys Tyr Val Thr Ser Ala Pro Met
 500 505 510
 Pro Glu Pro Gln Ala Pro Gly Arg Tyr Phe Ala His Ser Ile Leu Thr
 515 520 525
 Val Ser Glu Glu Glu Trp Asn Thr Gly Glu Thr Tyr Thr Cys Val Val
 530 535 540
 Ala His Glu Ala Leu Pro Asn Arg Val Thr Glu Arg Thr Val Asp Lys
 545 550 555 560
 Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val Met Ser Asp
 565 570 575
 Thr Ala Gly Thr Cys Tyr
 580

-continued

<210> SEQ ID NO 16
 <211> LENGTH: 213
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 16

```

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1           5           10           15
Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20           25           30
Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35           40           45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser
50           55           60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu
65           70           75           80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr
85           90           95
Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg Ala Val Ala Ala Pro
100          105          110
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115          120          125
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130          135          140
Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145          150          155          160
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165          170          175
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180          185          190
Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195          200          205
Asn Arg Gly Glu Cys
210

```

<210> SEQ ID NO 17
 <211> LENGTH: 211
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 17

```

Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
1           5           10           15
Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile
20           25           30
His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
35           40           45
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser
50           55           60
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
65           70           75           80

```


-continued

1	5	10	15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr	20	25	30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser	35	40	45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser	50	55	60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr	65	70	75
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys	85	90	95
Lys Val			

<210> SEQ ID NO 21
 <211> LENGTH: 104
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (3)..(3)
 <223> OTHER INFORMATION: Ala or Leu
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (65)..(65)
 <223> OTHER INFORMATION: Tyr or His

<400> SEQUENCE: 21

Gly Ser Xaa Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn	1	5	10	15
Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp	20	25	30	
Phe Leu Pro Asp Ser Ile Thr Leu Ser Trp Lys Tyr Lys Asn Asn Ser	35	40	45	
Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys	50	55	60	
Xaa Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln	65	70	75	80
Gly Thr Asp Glu His Val Val Cys Lys Val Gln His Pro Asn Gly Asn	85	90	95	
Lys Glu Lys Asn Val Pro Leu Pro	100			

<210> SEQ ID NO 22
 <211> LENGTH: 106
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu Gln Ser	1	5	10	15
Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln Leu Leu Cys	20	25	30	
Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp Leu Glu	35	40	45	
Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr Gln	50	55	60	
Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln Lys	65	70	75	80

-continued

His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly
85 90 95

His Thr Phe Glu Asp Ser Thr Lys Lys Cys
100 105

<210> SEQ ID NO 23
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: (69)..(69)
<223> OTHER INFORMATION: Pro or Thr
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: (87)..(87)
<223> OTHER INFORMATION: Gly or Ser

<400> SEQUENCE: 23

Val Ile Ala Glu Leu Pro Pro Lys Val Ser Val Phe Val Pro Pro Arg
1 5 10 15
Asp Gly Phe Phe Gly Asn Pro Arg Lys Ser Lys Leu Ile Cys Gln Ala
20 25 30
Thr Gly Phe Ser Pro Arg Gln Ile Gln Val Ser Trp Leu Arg Glu Gly
35 40 45
Lys Gln Val Gly Ser Gly Val Thr Thr Asp Gln Val Gln Ala Glu Ala
50 55 60
Lys Glu Ser Gly Xaa Thr Thr Tyr Lys Val Thr Ser Thr Leu Thr Ile
65 70 75 80
Lys Glu Ser Asp Trp Leu Xaa Gln Ser Met Phe Thr Cys Arg Val Asp
85 90 95
His Arg Gly Leu Thr Phe Gln Gln Asn Ala Ser Ser Met Cys
100 105 110

<210> SEQ ID NO 24
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
1 5 10 15

<210> SEQ ID NO 25
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser
1 5 10 15
Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val
20 25 30
Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg
35 40 45
Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln
50 55 60
Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg
65 70 75 80
Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His
85 90 95

-continued

Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser
100 105

<210> SEQ ID NO 26
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 26

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
1 5 10 15
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
20 25 30
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
35 40 45
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
50 55 60
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
65 70 75 80
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
85 90 95
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
100 105 110

<210> SEQ ID NO 27
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: {1}..(1)
<223> OTHER INFORMATION: Val or Gly
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: {6}..(6)
<223> OTHER INFORMATION: Thr or Ile
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: {12}..(12)
<223> OTHER INFORMATION: Ala or Ser
<400> SEQUENCE: 27

Xaa Pro Asp Gln Asp Xaa Ala Ile Arg Val Phe Xaa Ile Pro Pro Ser
1 5 10 15
Phe Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val
20 25 30
Thr Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp Thr Arg Gln
35 40 45
Asn Gly Glu Ala Val Lys Thr His Thr Asn Ile Ser Glu Ser His Pro
50 55 60
Asn Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Cys Glu Asp Asp
65 70 75 80
Trp Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu
85 90 95
Pro Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro Lys
100 105

<210> SEQ ID NO 28
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 28

Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp
 1 5 10 15
 Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe
 20 25 30
 Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu
 35 40 45
 Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser
 50 55 60
 Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu
 65 70 75 80
 Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro
 85 90 95
 Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys
 100 105 110

<210> SEQ ID NO 29

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
 1 5 10 15
 Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 20 25 30
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 35 40 45
 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
 50 55 60
 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
 65 70 75 80
 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
 85 90 95
 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 100 105

<210> SEQ ID NO 30

<211> LENGTH: 131

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Gly Val Ala Leu His Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg
 1 5 10 15
 Glu Gln Leu Asn Leu Arg Glu Ser Ala Thr Ile Thr Cys Leu Val Thr
 20 25 30
 Gly Phe Ser Pro Ala Asp Val Phe Val Gln Trp Met Gln Arg Gly Gln
 35 40 45
 Pro Leu Ser Pro Glu Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro
 50 55 60
 Gln Ala Pro Gly Arg Tyr Phe Ala His Ser Ile Leu Thr Val Ser Glu
 65 70 75 80
 Glu Glu Trp Asn Thr Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu
 85 90 95

-continued

Ala Leu Pro Asn Arg Val Thr Glu Arg Thr Val Asp Lys Ser Thr Gly
 100 105 110

Lys Pro Thr Leu Tyr Asn Val Ser Leu Val Met Ser Asp Thr Ala Gly
 115 120 125

Thr Cys Tyr
 130

<210> SEQ ID NO 31
 <211> LENGTH: 428
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Ala Ser Thr Gln Ser Pro Ser Val Phe Pro Leu Thr Arg Cys Cys Lys
 1 5 10 15

Asn Ile Pro Ser Asn Ala Thr Ser Val Thr Leu Gly Cys Leu Ala Thr
 20 25 30

Gly Tyr Phe Pro Glu Pro Val Met Val Thr Cys Asp Thr Gly Ser Leu
 35 40 45

Asn Gly Thr Thr Met Thr Leu Pro Ala Thr Thr Leu Thr Leu Ser Gly
 50 55 60

His Tyr Ala Thr Ile Ser Leu Leu Thr Val Ser Gly Ala Trp Ala Lys
 65 70 75 80

Gln Met Phe Thr Cys Arg Val Ala His Thr Pro Ser Ser Thr Asp Trp
 85 90 95

Val Asp Asn Lys Thr Phe Ser Val Cys Ser Arg Asp Phe Thr Pro Pro
 100 105 110

Thr Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro
 115 120 125

Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr
 130 135 140

Ile Asn Ile Thr Trp Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu
 145 150 155 160

Ser Thr Ala Ser Thr Thr Gln Glu Gly Glu Leu Ala Ser Thr Gln Ser
 165 170 175

Glu Leu Thr Leu Ser Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr
 180 185 190

Cys Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys
 195 200 205

Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro
 210 215 220

Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu
 225 230 235 240

Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser
 245 250 255

Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys
 260 265 270

Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr
 275 280 285

Arg Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro
 290 295 300

His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro
 305 310 315 320

Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly
 325 330 335

-continued

Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro
 340 345 350

Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp
 355 360 365

Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe
 370 375 380

Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys
 385 390 395 400

Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln
 405 410 415

Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys
 420 425

<210> SEQ ID NO 32
 <211> LENGTH: 330
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

-continued

275	280	285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn		
290	295	300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr		
305	310	315
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys		
325	330	
<210> SEQ ID NO 33		
<211> LENGTH: 453		
<212> TYPE: PRT		
<213> ORGANISM: Homo sapiens		
<400> SEQUENCE: 33		
Gly Ser Ala Ser Ala Pro Thr Leu Phe Pro Leu Val Ser Cys Glu Asn		
1	5	10
Ser Pro Ser Asp Thr Ser Ser Val Ala Val Gly Cys Leu Ala Gln Asp		
20	25	30
Phe Leu Pro Asp Ser Ile Thr Leu Ser Trp Lys Tyr Lys Asn Asn Ser		
35	40	45
Asp Ile Ser Ser Thr Arg Gly Phe Pro Ser Val Leu Arg Gly Gly Lys		
50	55	60
Tyr Ala Ala Thr Ser Gln Val Leu Leu Pro Ser Lys Asp Val Met Gln		
65	70	75
Gly Thr Asp Glu His Val Val Cys Lys Val Gln His Pro Asn Gly Asn		
85	90	95
Lys Glu Lys Asn Val Pro Leu Pro Val Ile Ala Glu Leu Pro Pro Lys		
100	105	110
Val Ser Val Phe Val Pro Pro Arg Asp Gly Phe Phe Gly Asn Pro Arg		
115	120	125
Lys Ser Lys Leu Ile Cys Gln Ala Thr Gly Phe Ser Pro Arg Gln Ile		
130	135	140
Gln Val Ser Trp Leu Arg Glu Gly Lys Gln Val Gly Ser Gly Val Thr		
145	150	155
Thr Asp Gln Val Gln Ala Glu Ala Lys Glu Ser Gly Pro Thr Thr Tyr		
165	170	175
Lys Val Thr Ser Thr Leu Thr Ile Lys Glu Ser Asp Trp Leu Gly Gln		
180	185	190
Ser Met Phe Thr Cys Arg Val Asp His Arg Gly Leu Thr Phe Gln Gln		
195	200	205
Asn Ala Ser Ser Met Cys Val Pro Asp Gln Asp Thr Ala Ile Arg Val		
210	215	220
Phe Ala Ile Pro Pro Ser Phe Ala Ser Ile Phe Leu Thr Lys Ser Thr		
225	230	235
Lys Leu Thr Cys Leu Val Thr Asp Leu Thr Thr Tyr Asp Ser Val Thr		
245	250	255
Ile Ser Trp Thr Arg Gln Asn Gly Glu Ala Val Lys Thr His Thr Asn		
260	265	270
Ile Ser Glu Ser His Pro Asn Ala Thr Phe Ser Ala Val Gly Glu Ala		
275	280	285
Ser Ile Cys Glu Asp Asp Trp Asn Ser Gly Glu Arg Phe Thr Cys Thr		
290	295	300
Val Thr His Thr Asp Leu Pro Ser Pro Leu Lys Gln Thr Ile Ser Arg		
305	310	315
		320

-continued

Pro	Lys	Gly	Val	Ala	Leu	His	Arg	Pro	Asp	Val	Tyr	Leu	Leu	Pro	Pro
			325						330					335	
Ala	Arg	Glu	Gln	Leu	Asn	Leu	Arg	Glu	Ser	Ala	Thr	Ile	Thr	Cys	Leu
			340					345					350		
Val	Thr	Gly	Phe	Ser	Pro	Ala	Asp	Val	Phe	Val	Gln	Trp	Met	Gln	Arg
			355				360					365			
Gly	Gln	Pro	Leu	Ser	Pro	Glu	Lys	Tyr	Val	Thr	Ser	Ala	Pro	Met	Pro
			370				375				380				
Glu	Pro	Gln	Ala	Pro	Gly	Arg	Tyr	Phe	Ala	His	Ser	Ile	Leu	Thr	Val
			385			390				395					400
Ser	Glu	Glu	Glu	Trp	Asn	Thr	Gly	Glu	Thr	Tyr	Thr	Cys	Val	Val	Ala
				405					410					415	
His	Glu	Ala	Leu	Pro	Asn	Arg	Val	Thr	Glu	Arg	Thr	Val	Asp	Lys	Ser
			420					425					430		
Thr	Gly	Lys	Pro	Thr	Leu	Tyr	Asn	Val	Ser	Leu	Val	Met	Ser	Asp	Thr
		435					440					445			
Ala	Gly	Thr	Cys	Tyr											
			450												

The invention claimed is:

1. A binding molecule having a penta- or hexameric ring structure comprising five or six bispecific binding units, wherein each of said bispecific binding units has the same two binding specificities and comprises a first chain comprising at least a C μ 4 domain, a C μ 3 domain, and a C μ 2 domain of a human IgM heavy chain constant region conjugated to a first binding region to a first binding target, and a second chain comprising at least a C μ 4, a C μ 3 domain, and a C μ 2 domain of a human IgM heavy chain constant region conjugated to a second binding region to a second binding target, wherein said first and second binding targets are different, and wherein said first and second chains are assembled to create a bispecific binding unit as a result of an asymmetric interface created between their respective IgM heavy chain constant regions, wherein the asymmetric interface is created by (i) a salt bridge formed by one or more pair-wise switches between oppositely charged amino acid residues in at least one of the C μ 2, C μ 3 and/or C μ 4 domains of the two chains of said binding unit, wherein the one or more pair-wise switches between oppositely charged amino acid residues comprise:

C μ 4 R328E,D $\leftrightarrow$ C μ 4 E339R,K;
 C μ 4 R344E,D $\leftrightarrow$ C μ 4 D330R,K;
 C μ 4 K376E,D $\leftrightarrow$ C μ 4 E385R,K;
 C μ 4 R427E,D $\leftrightarrow$ C μ 4 E339R,K;
 C μ 4 T354F,D $\leftrightarrow$ C μ 4 I397R,K;
 C μ 2 E167R,K $\leftrightarrow$ C μ 2 K177E,D;
 C μ 2 K169E,D $\leftrightarrow$ C μ 2 E170R,K;
 C μ 2 D121K,R $\leftrightarrow$ C μ 4 K315D,E;
 or
 C μ 2 K185D,E $\leftrightarrow$ C μ 4 D360K,R;
 or

(ii) through knobs-into-holes connections comprising: knob T350Y and holes L352S and H395V; or knobs T350Y, T354E, and I397E and holes L352S, T354K, I1395V, and I397K; and

wherein the amino acid coordinates correspond to the wild-type human IgM heavy chain constant region of SEQ ID NO: 33.

25

2. The binding molecule of claim 1, wherein said bispecific binding units are identical.

3. The binding molecule of claim 1, wherein said first and second binding regions are two different IgM antibody heavy chain variable regions, binding to said first and said second binding targets, respectively.

4. The binding molecule of claim 3, further comprising at least one IgM light chain variable region sequence associated with at least one of said two different IgM heavy chain variable regions.

5. The binding molecule of claim 4, wherein said light chain variable region sequence is coupled to its matching heavy chain variable region by creating an asymmetric interface between the light and heavy chains.

6. A multi-specific binding molecule having a penta- or hexameric ring structure comprising five or six bispecific binding units, wherein (i) each of said bispecific binding units comprises two human IgM heavy chain constant regions each comprising at least a C μ 2, C μ 3 and C μ 4 domain conjugated to a binding region to a binding target, (ii) at least two of said bispecific binding units bind to different binding targets, (iii) an internal asymmetric interface is created between two IgM heavy chain constant regions of each bispecific binding unit, and (iv) an external asymmetric interface is created between the heavy chain constant regions of the neighboring bispecific binding units binding to different targets, wherein the internal asymmetric interface is created by: (a) a salt bridge formed by one or more pair-wise switches between oppositely charged amino acid residues in at least one of the C μ 2, C μ 3 and/or C μ 4 domains of the two chains of said binding unit, wherein the one or more pair-wise switches between oppositely charged amino acid residues comprise:

C μ 4 R328E,D $\leftrightarrow$ C μ 4 E339R,K;
 C μ 4 R344E,D $\leftrightarrow$ C μ 4 D330R,K;
 C μ 4 K376E,D $\leftrightarrow$ C μ 4 E385R,K;
 C μ 4 R427E,D $\leftrightarrow$ C μ 4 E339R,K;
 C μ 4 T354E,D $\leftrightarrow$ C μ 4 I397R,K;
 C μ 2 E167R,K $\leftrightarrow$ C μ 2 K177E,D;
 C μ 2 K169E,D $\leftrightarrow$ C μ 2 E170R,K;
 C μ 2 D121K,R $\leftrightarrow$ C μ 4 K315D,E;

- or
C μ 2 K185D,E $\leftrightarrow$ C μ 4 D360K,R
or
(b) through knobs-into-holes connections comprising:
knob T350Y and holes L352S and H395V; or knobs
T350Y, T354E, and I397E and holes L352S, T354K,
H395V, and I397K; and
wherein the amino acid coordinates correspond to the
wild-type human IgM heavy chain constant region of
SEQ ID NO: 33.
7. The multi-specific binding molecule of claim 6,
wherein the external asymmetric interface is created by at
least one pair-wise charged amino acid residue switch in the
C μ 3-C μ 3 domains.
8. The multi-specific binding molecule of claim 7,
wherein the pair-wise charged amino acid switch in the
C μ 3-C μ 3 domain is K238 $\leftrightarrow$ D293 or K268 $\leftrightarrow$ D294, the
amino acid coordinates corresponding to the wild-type
human IgM heavy chain constant region of SEQ ID NO:33.
9. A multi-specific binding molecule having a penta- or
hexameric ring structure comprising five or six monospecific
binding units, wherein (i) each of said monospecific binding
units comprises two human IgM heavy chain constant
regions each comprising at least a C μ 2, C μ 3 and C μ 4 domain
conjugated to a binding region to a binding target, (ii) at least
two of said monospecific binding units bind to different
binding targets, and (iii) an external asymmetric interface is
created between the heavy chain constant regions of the
neighboring monospecific binding units that bind to different
binding targets, wherein the external asymmetric interface is
created by at least one pair-wise charged amino acid residue
switch in the C μ 3-C μ 3 domains,
wherein the pair-wise charged amino acid switch is
K238 $\leftrightarrow$ D293 or K268 $\leftrightarrow$ D294, and wherein the amino
acid coordinates correspond to the wild-type human
IgM heavy chain constant region of SEQ ID NO: 33,
and
wherein the pair-wise charged amino acid switch is
selected from the group consisting of K $\rightarrow$ E, K $\rightarrow$ D,
D $\rightarrow$ K, and D $\rightarrow$ R.
10. The multi-specific binding molecule of claim 9 or
claim 6, further comprising at least one IgM light chain
variable region sequence associated with at least one of said
two different IgM heavy chain variable regions.
11. The multi-specific binding molecule of claim 10,
wherein said light chain variable region sequence is coupled

to its matching heavy chain variable region by creating an
asymmetric interface between the light and heavy chains.

12. The binding molecule of any one of claim 1, 9, or 6,
wherein the binding targets are selected from peptides,
polypeptides, glycoproteins, nucleic acid molecules, organic
and non-organic small molecules, such as soluble polypep-
tides, cell surface receptors, ligands, molecular transporters,
enzymes and substrates of enzymes.

13. The binding molecule of any one of claim 1, 9, or 6,
wherein the binding units binding to different targets are
selected from the group consisting of binding units binding
to sites on the same soluble target; sites on the same cell
surface receptor target; different soluble targets; different
cell surface receptor targets; soluble and cell surface recep-
tor targets; soluble or cell surface receptor and long resi-
dence time targets; soluble and matrix protein or substrate
targets; soluble or receptor and molecular transporter targets,
and different cell types.

14. The binding molecule of any one of claim 1, 9, or 6,
further comprising an IgM J chain.

15. The binding molecule of any one of claim 1, 9, or 6,
wherein at least one of said binding regions is a variable
region of an antibody, such as an IgM antibody.

16. The binding molecule of any one of claim 1, 9, or 6,
conjugated to a toxin or a chemotherapeutic agent.

17. The binding molecule according to claim 16, wherein
the conjugation is by fusion or by a chemical linker.

18. The binding molecule of any one of claim 1, 9, or 6,
which is chimeric or humanized.

19. A pharmaceutical composition comprising the binding
molecule according to any one of claims 1, 9, 6, and a
pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the binding
molecule according to claim 16 and a pharmaceutically
acceptable carrier.

21. A method of treating a subject having cancer, the
method comprising administering an effective amount of the
pharmaceutical composition according to claim 19 to the
subject.

22. A method of treating a subject having cancer, the
method comprising administering an effective amount of the
pharmaceutical composition according to claim 20 to the
subject.

* * * * *